

1 **Discovery and systematic characterization of risk variants and genes for** 2 **coronary artery disease in over a million participants**

3
4 Krishna G Aragam^{1,2,3,4*}, Tao Jiang^{5*}, Anuj Goel^{6,7*}, Stavroula Kanoni^{8*}, Brooke N Wolford^{9*},
5 Elle M Weeks⁴, Minxian Wang^{3,4}, George Hindy¹⁰, Wei Zhou^{4,11,12,9}, Christopher Grace^{6,7},
6 Carolina Roselli³, Nicholas A Marston¹³, Frederick K Kamanu¹³, Ida Surakka¹⁴, Loreto Muñoz
7 Venegas^{15,16}, Paul Sherliker¹⁷, Satoshi Koyama¹⁸, Kazuyoshi Ishigaki¹⁹, Bjørn O Åsvold^{20,21,22},
8 Michael R Brown²³, Ben Brumpton^{20,21}, Paul S de Vries²³, Olga Giannakopoulou⁸, Panagiota
9 Giardoglou²⁴, Daniel F Gudbjartsson^{25,26}, Ulrich Guldener²⁷, Syed M. Ijlal Haider¹⁵, Anna
10 Helgadottir²⁵, Mayssoon Ibrahim²⁸, Adnan Kastrati^{27,29}, Thorsten Kessler^{27,29}, Ling Li²⁷, Lijiang
11 Ma^{30,31}, Thomas Meitinger^{32,33,29}, Sören Mucha¹⁵, Matthias Munz¹⁵, Federico Murgia²⁸, Jonas B
12 Nielsen^{34,20}, Markus M Nöthen³⁵, Shichao Pang²⁷, Tobias Reinberger¹⁵, Gudmar Thorleifsson²⁵,
13 Moritz von Scheidt^{27,29}, Jacob K Ulirsch^{4,11,36}, EPIC-CVD Consortium, Biobank Japan, David O
14 Arnar^{25,37,38}, Deepak S Atri^{39,3}, Noël P Burt⁴, Maria C Costanzo⁴, Jason Flannick⁴⁰, Rajat M
15 Gupta^{39,3,4}, Kaoru Ito¹⁸, Dong-Keun Jang⁴, Yoichiro Kamatani⁴¹, Amit V Khera^{2,3,4}, Issei
16 Komuro⁴², Iftikhar J Kullo⁴³, Luca A Lotta⁴⁴, Christopher P Nelson⁴⁵, Robert Roberts⁴⁶,
17 Gudmundur Thorgeirsson^{25,37,38}, Unnur Thorsteinsdottir^{25,37}, Thomas R Webb⁴⁵, Aris Baras⁴⁴,
18 Johan LM Björkegren^{47,48,49}, Eric Boerwinkle^{23,50}, George Dedoussis²⁴, Hilma Holm²⁵, Kristian
19 Hveem^{20,21}, Olle Melander⁵¹, Alanna C Morrison²³, Marju Orho-Melander⁵¹, Loukianos S
20 Rallidis⁵², Arno Ruusalepp⁵³, Marc S Sabatine¹³, Kari Stefansson^{25,37}, Pierre Zalloua^{54,55}, Patrick
21 T Ellinor^{1,3}, Martin Farrall^{6,7}, John Danesh^{5,56,57,58,59,60}, Christian T Ruff¹³, Hilary K Finucane^{4,11,12},
22 Jemma C Hopewell²⁸, Robert Clarke²⁸, Jeanette Erdmann^{15,61†}, Nilesh J Samani^{45†}, Heribert
23 Schunkert^{27,29†}, Hugh Watkins^{6,7†}, Cristen J Willer^{14,9,62†}, Panos Deloukas^{8,63†}, Sekar
24 Kathiresan^{64†}, Adam S Butterworth^{5,56,60,59,57†} on behalf of the CARDIoGRAMplusC4D
25 Consortium.

26
27 * Contributed equally.

28 † Jointly supervised the work.

29
30
31 ¹Cardiovascular Research Center, Massachusetts General Hospital, 185 Cambridge St., Boston, MA,
32 02114, USA

33 ²Center for Genomic Medicine, Massachusetts General Hospital, 185 Cambridge St., Boston, MA, 02114,
34 USA

35 ³Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, 75 Ames St., Cambridge, MA,
36 02142, USA

37 ⁴Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, 75 Ames St.,
38 Cambridge, MA, 02142, USA

39 ⁵BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of
40 Cambridge, Worts Causeway, Cambridge, CB1 8RN, UK

41 ⁶Radcliffe Department of Medicine, Division of Cardiovascular Medicine, University of Oxford, Headley
42 Way, Oxford, OX3 9DU, UK

43 ⁷Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK

- 44 ⁸William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary
45 University of London, Charterhouse square, London, EC1M 6BQ, UK
- 46 ⁹Department of Computational Medicine & Bioinformatics, University of Michigan, Palmer Ave., Ann
47 Arbor, Michigan, 48109, USA
- 48 ¹⁰Department of Population Medicine, Qatar University College of Medicine, Doha, Qatar
- 49 ¹¹Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts,
50 02114, USA
- 51 ¹²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge,
52 Massachusetts, USA
- 53 ¹³TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard
54 Medical School, 60 Fenwood Rd., Boston, Massachusetts, 02115, USA
- 55 ¹⁴Department of Internal Medicine, Cardiology, University of Michigan, E. Catherine St., Ann Arbor,
56 Michigan, 48109, USA
- 57 ¹⁵Institute for Cardiogenetics, University of Lübeck, Lübeck, 23562, Germany
- 58 ¹⁶DZHK (German Research Center for Cardiovascular Research), partner site Hamburg-Lübeck-Kiel,
59 Lübeck, Germany
- 60 ¹⁷Medical Research Council Population Health Research Unit, CTSU - Nuffield Department of Population
61 Health, Medical Sciences Division, University of Oxford, Roosevelt Drive, Oxford, OX3 7LF, UK
- 62 ¹⁸Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical
63 Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan
- 64 ¹⁹Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, 1-
65 7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan
- 66 ²⁰K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Norwegian
67 University of Science and Technology, NTNU, Trondheim, Norway
- 68 ²¹HUNT Research Centre, Norwegian University of Science and Technology, Levanger, Norway
- 69 ²²Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim, Norway
- 70 ²³Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences,
71 School of Public Health, The University of Texas Health Science Center at Houston, 1200 Pressler St.,
72 Houston, TX, 77030, USA
- 73 ²⁴School of Health Science & Education, Department of Nutrition-Dietetics, Harokopio University,
74 Eleftheriou Venizelou 70, Athens, 176 71, Greece
- 75 ²⁵deCODE genetics/Amgen, Inc., Sturlugata 8, Reykjavik, 102, Iceland
- 76 ²⁶School of Engineering and Natural Sciences, University of Iceland, Sæmundargötu 2, Reykjavik, 102,
77 Iceland
- 78 ²⁷German Heart Centre Munich, Department of Cardiology, Technical University of Munich, Lazarettstr.
79 36, Munich, 80636, Germany
- 80 ²⁸CTSU - Nuffield Department of Population Health, Medical Sciences Division, University of Oxford,
81 Roosevelt Drive, Oxford, OX3 7LF, UK
- 82 ²⁹German Research Center for Cardiovascular Research (DZHK e.V.), partner site Munich Heart Alliance,
83 Lazarettstr. 36, Munich, 80636, Germany
- 84 ³⁰Department of Genetics and Genomic Science, Icahn Institute for Genomics and Multiscale Biology,
85 Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA
- 86 ³¹The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai,
87 New York, NY, 10029, USA
- 88 ³²Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental
89 Health, Neuherberg, Germany
- 90 ³³Klinikum rechts der Isar, Institute of Human Genetics, Technical University of Munich, Munich, Germany
- 91 ³⁴Department of Internal Medicine, Cardiology, University of Michigan, E. Catherine St., Ann Arbor,
92 Michigan, 48109, US

- 93 ³⁵School of Medicine & University Hospital Bonn, Institute of Human Genetics, University of Bonn, Bonn,
94 Germany
- 95 ³⁶Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts,
96 02115, USA
- 97 ³⁷Faculty of Medicine, University of Iceland, Sæmundargötu 2, Reykjavik, 102, Iceland
- 98 ³⁸Department of Internal Medicine, Division of Cardiology, Landspítali – National University Hospital of
99 Iceland, Hringbraut, Reykjavik, 101, Iceland
- 100 ³⁹Divisions of Cardiovascular Medicine and Genetics, Brigham and Women's Hospital, Harvard Medical
101 School, 75 Francis St., Boston, MA, 02115, USA
- 102 ⁴⁰Division of Genetics and Genomics, Boston Children's Hospital, 300 Longwood Ave., Boston, MA,
103 02115, USA
- 104 ⁴¹Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences,
105 The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Tokyo, 108-8639, Japan
- 106 ⁴²Department of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo,
107 Tokyo, 113-8655, Japan
- 108 ⁴³Department of Cardiovascular Medicine, Mayo Clinic, MN, USA
- 109 ⁴⁴Regeneron Genetics Center, Regeneron Pharmaceuticals, 777 Old Saw Mill River Rd., Tarrytown, NY,
110 10591, USA
- 111 ⁴⁵Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of
112 Leicester, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK
- 113 ⁴⁶Cardiovascular Genomics & Genetics, University of Arizona, College of Medicine, Phoenix, Arizona,
114 USA
- 115 ⁴⁷Clinical Gene Networks AB, Stockholm, Sweden
- 116 ⁴⁸Department of Genetics & Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn
117 School of Medicine at Mount Sinai, New York, USA
- 118 ⁴⁹Integrated Cardio Metabolic Centre, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge,
119 Sweden
- 120 ⁵⁰Human Genome Sequencing Center, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030,
121 USA
- 122 ⁵¹Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden
- 123 ⁵²Second Department of Cardiology, Medical School, National and Kapodistrian University of Athens,
124 University General Hospital Attikon, Athens, Greece
- 125 ⁵³Department of Cardiac Surgery and The Heart Clinic, Tartu University Hospital, Tartu, Estonia
- 126 ⁵⁴University of Balamand, East Med Res Institute, School of Medicine, P.O. Box 33, Amioun, Lebanon
- 127 ⁵⁵Harvard T.H.Chan School of Public Health, Boston, MA, USA
- 128 ⁵⁶Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge,
129 Cambridge, UK
- 130 ⁵⁷The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and
131 Genomics at the University of Cambridge, Cambridge, UK
- 132 ⁵⁸Human Genetics, Wellcome Sanger Institute, Saffron Walden, UK
- 133 ⁵⁹National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge University
134 Hospitals, Cambridge, UK
- 135 ⁶⁰British Heart Foundation Centre of Excellence, Division of Cardiovascular Medicine, Addenbrooke's
136 Hospital, Hills Road, Cambridge, UK
- 137 ⁶¹DZHK (German Research Center for Cardiovascular Research), partner site Hamburg-Lübeck-Kiel,
138 23562, Germany
- 139 ⁶²Department of Human Genetics, University of Michigan, E. Catherine St., Ann Arbor, Michigan, 48109,
140 USA
- 141 ⁶³Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD),

142 King Abdulaziz University, Jeddah, Saudi Arabia
143 ⁶⁴Verve Therapeutics, Cambridge, MA, 02139, USA

144

145

146 Correspondence to Adam Butterworth (asb38@medschl.cam.ac.uk) or Krishna Aragam
147 (karagam@broadinstitute.org).

148

149

150 **ABSTRACT**

151 Rapid progress of the discovery of genetic loci associated with common, complex diseases has
152 outpaced the elucidation of mechanisms pertinent to disease pathogenesis. To address relevant
153 barriers for coronary artery disease (CAD), we combined genetic discovery analyses with
154 downstream characterization of likely causal variants, genes, and biological pathways.
155 Specifically, we conducted a genome-wide association study (GWAS) comprising 181,522 cases
156 of CAD among 1,165,690 participants. We detected 241 associations, including 54 associations
157 and 30 loci not previously linked to CAD. Next, we prioritized likely causal variants using
158 functionally-informed fine-mapping, yielding 42 associations with fewer than five variants in the
159 95% credible set. Combining eight complementary predictors, we prioritized 185 candidate causal
160 genes, including 94 genes supported by three or more predictors. Similarity-based clustering
161 underscored a role for early developmental processes, cell cycle signaling, and vascular
162 proliferation in the pathogenesis of CAD. Our analysis identifies and systematically characterizes
163 risk loci for CAD to inform experimental interrogation of putative causal mechanisms for CAD.

164

165 **INTRODUCTION**

166 Coronary artery disease (CAD) remains the leading global cause of mortality, principally reflecting
167 effects of risk behaviors and genetic susceptibility.[1] Previous genetic association studies have
168 identified over 200 susceptibility loci for CAD. Consistent with other common, complex diseases,
169 genetic discovery analyses have identified the polygenic architecture of CAD, enabled insights
170 into disease etiology and causal risk factors, and facilitated the development of novel tools for
171 clinical risk prediction.[2-10] However, with rapid increases in the availability of large-scale human
172 genetic data linked to health outcomes, the identification of disease-associated genetic loci has
173 outpaced their ensuing functional characterization.

174

175 Several *in silico* tools have emerged to help determine the mechanisms connecting regions of the
176 genome to disease risk.[11, 12] Nonetheless, it remains fundamentally challenging to identify the
177 causal genes underlying genetic associations as these tools can produce spurious findings and
178 frequently lack consensus.[13] Recent analyses have suggested the value of integrating locus-
179 specific (“locus-based”) approaches to gene prioritization with more global (“similarity-based”)
180 assessments of shared pathways and functions to enhance the prediction of putative causal
181 genes.[13-15] The integration of multiple orthogonal lines of evidence, and the use of disease-
182 specific resources to aid variant and gene classifications, may expedite the transition from gene
183 maps to disease mechanisms.

184

185 To extend these approaches to CAD, we first analyzed imputed genotyping array data from ten
186 studies, comprising over 120,000 cases of CAD and 700,000 controls. We then combined these

187 results with summary statistics from the CARDIoGRAMplusC4D Consortium, achieving a total
188 sample of 181,522 CAD cases among 1,165,690 study participants.[2, 7, 10, 16] Our primary
189 objectives were to: (1) discover novel genetic associations with CAD; (2) determine the impact of
190 expanded genetic discovery for identifying loci of biological relevance and improving clinical risk
191 prediction; and (3) implement a systematic and integrative approach – including well-established
192 and newer methods – to prioritize likely causal variants and genes at genome-wide significant
193 associations for CAD, thereby providing a catalogue of high-priority testable hypotheses for
194 experimental follow-up.

195

196

197 **RESULTS**

198 Discovery of known and novel CAD loci

199 Participants were largely (>95%) of European ancestry (predominantly from Europe or the US)
200 and 46% were female (Supplementary Table 1). After quality control and filtering, 20,073,070
201 variants were included in the discovery meta-analysis (Online Methods). To identify independent
202 variants, we performed approximate conditional analysis using GCTA-COJO, and report 241
203 independently associated variants that exceeded genome-wide significance ($p\text{-value}\leq 5.0\times 10^{-8}$) at
204 198 loci (Supplementary Table 2; Supplementary Figure 1). 54 sentinel variants were
205 uncorrelated ($r^2<0.2$) with variants reported in previous large-scale genetic analyses, including 30
206 that lie outside genomic regions previously reported for CAD (**Table 1**). A phenome-wide
207 association scan (PheWAS) in UK Biobank indicated that 130 (54%) of the 241 CAD-associated
208 variants were not associated ($p\text{-value}>3.9\times 10^{-6}$) with conventional CAD risk factors such as blood
209 lipids, blood pressure, type 2 diabetes, or adiposity (Supplementary Table 3), suggesting
210 widespread mediation of CAD risk via other mechanisms.

211

212 Several of the novel associations (**Table 1**) were found near mechanistically plausible causal
213 genes, including: rs35611688 near *ACVR2A*, which encodes a receptor for activin A, a member
214 of the transforming growth factor (TGF)-beta superfamily of cytokines implicated in
215 atherogenesis;[17-19] rs6883598 near *FBN2*, encoding fibrillin-2, which mediates the early stages
216 of elastic fiber assembly and is associated with aortic aneurysms and Beals Syndrome, a Marfan-
217 like disorder;[20-22] and rs1892971 near *MMP13*, which encodes matrix metalloproteinase
218 (MMP)-13, an interstitial collagenase that influences the structural integrity of atherosclerotic
219 plaques through regulation and organization of intraplaque collagen.[23, 24] While the sentinel
220 variant near *FBN2* was associated with blood pressure and hypertension in the PheWAS, the lead
221 variants near *ACVR2A* and *MMP13* were not associated with conventional CAD risk factors,
222 suggesting they are likely to act through alternative pathways.

223

224 Allelic architecture

225 Of the 54 novel associations, 46 sentinel variants were common (minor allele frequency
226 [MAF]>0.05) with relatively weak effects on CAD (odds ratio [OR] per CAD risk allele from 1.03-
227 1.07) (**Figure 1**). The remaining eight were low-frequency (MAF=0.009 to 0.036), of which four
228 had comparatively strong effects (OR=1.30 to 1.44) and four had more modest effect associations
229 (OR=1.10 to 1.14) (Supplementary Figure 2). To boost power to detect associations driven by
230 rarer variants, we conducted gene-based tests of missense and predicted loss-of-function
231 variants in UK Biobank (n=33,941 CAD cases, 438,394 controls; Supplementary Table 4). Apart
232 from a strong signal for *PCSK9*, we did not find evidence for further association with a burden of
233 low-frequency or rare variants (Supplementary Figure 3; Supplementary Table 5).

234

235 Differential effects by sex

236 To identify associations that differ by sex, we conducted sex-stratified GWAS in a subset of 16
237 studies comprising 77,080 CAD cases (Supplementary Table 6). After combining results across
238 studies using a sex-differentiated meta-analysis, which allows for between-sex heterogeneity, we
239 found ten associations (nine previously reported) that reached genome-wide significance (p-
240 value $\leq 5.0 \times 10^{-8}$) and had evidence (p-value ≤ 0.01) for between-sex heterogeneity (Supplementary
241 Table 7). Nine of these had stronger effects in the male-only analysis - including associations at
242 the well-known 9p21 and *SORT1* loci - however rs7696877 near *MYOZ2* had a stronger effect in
243 females (per-allele OR=0.94) than males (per-allele OR=0.98; heterogeneity p-value=0.007).

244

245 Sub-threshold associations

246 At a significance level (p-value $< 2.52 \times 10^{-5}$) approximating a 1% false discovery rate (FDR), we
247 identified a further 47,622 variants associated with CAD, including 656 conditionally independent
248 associations (Supplementary Table 8). The majority (486, 74.1%) were common variants
249 (MAF>0.05), but almost all had relatively weak effects (per-allele OR<1.07). Among these were
250 several associations with strong biological priors, including rs41279633 (p-value $= 1.24 \times 10^{-6}$) in
251 *NPC1L1*, which encodes Niemann-Pick C1-like 1, an important mediator of intestinal cholesterol
252 absorption and the target of ezetimibe, a cholesterol lowering drug. Other examples include loci
253 known to be associated with cardiovascular risk factors, such as *PNPLA3* (rs738408; p-
254 value $= 1.04 \times 10^{-5}$), the strongest locus for non-alcoholic fatty liver disease[25], and *TCF7L2*
255 (rs7903146; p-value $= 6.39 \times 10^{-8}$), the strongest locus for type 2 diabetes[26]. Heritability for liability
256 to CAD was estimated to be 15.5% for the 241 conditionally independent associations reaching
257 genome-wide significance, increasing to 36.1% for the 897 associations with p-value $< 2.52 \times 10^{-5}$.

258

259 Trans-ethnic comparison and meta-analysis

260 The recent publication of a large GWAS from Biobank Japan permitted evaluation of the genome-
261 wide associations in a well-powered set of East Asian ancestry participants.[3] Effect estimates
262 for the 199 sentinel variants in both datasets were strongly positively correlated ($r=0.59$) between
263 the predominantly European ancestry meta-analysis and the Biobank Japan GWAS
264 (Supplementary Figure 4a), as were the effect allele frequencies ($r=0.76$; Supplementary Figure
265 4b). To assess the potential for enhanced discovery by combining results from different ethnic
266 groups, we then meta-analyzed the Biobank Japan GWAS summary statistics with those from the
267 current analysis, yielding 38 additional novel loci at genome-wide significance (Supplementary
268 Table 9). 36 of these were included in the 1% FDR set, including the aforementioned associations
269 at *TCF7L2* and *PNPLA3*. The exceptions were two variants (rs5867305 in *SKP2* and rs75655731
270 near *LINC00599*) that are considerably more common in East Asians and had stronger effect
271 estimates in Biobank Japan (Supplementary Table 9).

272

273 Association of polygenic risk scores with incident and recurrent CAD

274 To assess the impact of the enhanced discovery sample size on genetic risk prediction for CAD,
275 we constructed and evaluated 362 polygenic risk scores (PRS) using combinations of PRS
276 derivation methods (Pruning and Thresholding[27] or LDpred algorithm[28]) and summary
277 statistics from either the current meta-analysis or a 1000 Genomes-imputed GWAS involving
278 around 60,000 CAD cases published in 2015.[7] We selected the optimized PRS for each
279 combination of derivation method and GWAS summary statistics based on performance when
280 predicting incident CAD in a training dataset from the Malmo Diet and Cancer study ($n=22,872$;
281 $n_{\text{incident_cases}}=3,307$) (Supplementary Table 10). The two top-performing scores were those derived
282 with LDpred, which comprised 2,324,653 variants (“2021 PRS”) and 1,532,758 variants (“2015
283 PRS”; Supplementary Tables 11-14). In bootstrapping analyses, the 2021 PRS outperformed the
284 2015 PRS as evidenced by greater effect estimates (age- and sex-adjusted mean hazard ratio
285 [HR]=1.56 versus 1.49; $p\text{-value}=3.2\times 10^{-31}$) and higher area under the receiver operator
286 characteristic curve (AUC; age- and sex-adjusted mean AUC=0.742 versus 0.736; $p\text{-}$
287 $\text{value}=6.5\times 10^{-16}$) (Supplementary Table 15).

288

289 We validated both scores in a held-out subset of the Malmo Diet and Cancer study ($n=5,685$;
290 $n_{\text{incident_cases}}=815$) (Supplementary Table 10). The 2021 PRS was more strongly associated with
291 incident CAD with greater age- and sex-adjusted hazards per 1-SD higher PRS (HR 1.61; 95%
292 CI 1.50-1.72) than the 2015 PRS (HR 1.49 per standard deviation; 95% CI 1.39-1.59), providing
293 improved stratification of participants at higher and lower risk for incident CAD (**Figure 2a**). After
294 adjustment for several established risk factors (total cholesterol, HDL cholesterol, systolic blood
295 pressure, body mass index, type 2 diabetes, current smoking status, and family history of CAD),
296 the 2021 PRS remained strongly associated with incident events (HR 1.54 per SD higher PRS;
297 95% CI: 1.42-1.66). Examining the extremes of CAD risk, the 2021 PRS yielded a 5.7-fold higher
298 risk between the top and bottom deciles of the PRS, compared to a 3.8-fold higher risk with the
299 2015 PRS.

300

301 To assess the value of the PRS for secondary prevention, we evaluated both PRS for prediction
302 of recurrent coronary events in the placebo arm of the Further Cardiovascular Outcomes
303 Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER; n=7,135;
304 $n_{\text{incident_cases}}=673$) clinical trial, a cohort of patients with established atherosclerotic cardiovascular
305 disease.[29] The 2021 PRS demonstrated improved recurrent event prediction (HR 1.20 per SD
306 higher PRS; 95% CI: 1.11-1.29) as compared to the 2015 PRS (HR 1.13 per SD higher PRS;
307 95% CI: 1.04-1.22), and enhanced stratification of participants at higher and lower risk for
308 secondary events (**Figure 2b**). Examining the extremes of risk, the 2021 PRS yielded a 1.7-fold
309 higher risk of recurrent coronary events between the top and bottom deciles of the PRS versus a
310 1.4-fold higher risk with the 2015 PRS.

311

312 Prioritizing causal variants, genes and intermediate pathways

313 We employed several independent approaches to prioritize causal variants, effector genes,
314 relevant tissues of action and related intermediate causal pathways for all 241 genome-wide
315 significant associations. Presence of a protein-altering (i.e. missense or predicted loss-of-
316 function) variant has been shown to be a strong predictor of a causal gene, particularly if the
317 coding variant is not common in the population[14]. At 44 of the 241 genome-wide significant
318 associations, the sentinel variant, or a strong proxy ($r^2 \geq 0.8$), was a protein-altering variant
319 (Supplementary Table 16). These included well-known low-frequency missense variants in
320 *PCSK9* (p.R46L), *LPL* (p.N291S), and *ANGPTL4* (p.E40K)[16]. Eleven of the 44 missense
321 variants were novel, including a missense variant in *RRBP1* (rs1132274; p.R891Q) that was also
322 the CAD sentinel variant. *RRBP1* encodes ribosome binding protein 1, a widely-expressed protein
323 responsible for protein processing in the membrane of the endoplasmic reticulum. We also
324 identified a missense variant (rs129415; p.G398R) in *SCUBE1* that is strongly correlated with the
325 CAD sentinel variant in European ancestry participants ($r^2=0.99$). *SCUBE1* encodes signal
326 peptide-CUB-EGF domain-containing protein 1, a glycoprotein secreted by activated platelets that
327 protects against thrombosis in mice when inhibited.[30]

328

329 Functionally-informed fine-mapping

330 Incorporating functional annotations into fine-mapping approaches has been shown to improve
331 identification of likely causal variants at associated loci.[31-33] Using ChromHMM-derived
332 chromatin states from the NIH Roadmap Epigenomics Consortium to functionally annotate the
333 genome, we found greater than 2-fold enrichment for these states in the ten CAD relevant
334 cell/tissue types we tested, consistent with the findings in a previous GWAS meta-analysis
335 (Supplementary Table 17).[7] Of 197 distance-based regions containing genome-wide significant
336 associations, we found 116 (58.9%) regions with significant enrichment in at least one tissue type
337 (Supplementary Table 18). The majority (69; 59.5%) were relatively tissue-specific, showing

338 enrichment in only one or two tissue types, but eight regions showed widespread enrichment in
339 seven or more tissues (**Figure 3a**). Adipose (n=28), liver (n=24) and aorta (n=21) were the tissues
340 that showed the greatest enrichment for the most regions, reflecting their importance in the
341 etiology of CAD (Supplementary Table 18).

342

343 We applied a functionally-informed fine-mapping method (FGWAS),[32] which uses the chromatin
344 state enrichment information to reweight GWAS summary statistics and compute variant-specific
345 posterior probabilities of association (PPA). Across the 116 enriched regions we identified 1,456
346 potential causal variants among the 95% credible sets (Supplementary Table 19). Forty-two
347 enriched regions contained fewer than five 95% credible variants (**Figure 3b**), while 49 regions
348 contained a variant with posterior probability of association (PPA) ≥ 0.5 (**Figure 3c**; Supplementary
349 Table 20), showing that the combination of functional annotation and high statistical power can
350 pinpoint likely causal variants. Indeed, 13 regions were fine-mapped to just a single variant
351 credible set, including missense variants in *PCSK9*, *ANGPTL4* and *APOE*, plus other well-studied
352 non-coding variants, such as rs9349379 near *PHACTR1/EDN1*,[34] and rs2107595 near
353 *HDAC9/TWIST1*. [35]

354

355 At 10 loci, functionally-informed fine-mapping prioritized variants that did not have the strongest
356 statistical association. For example, at the LDL-cholesterol and adiposity-associated *MAFB*
357 locus,[36] the CAD sentinel variant was rs2207132 (OR=1.10, 95%CI=1.07-1.13; p-value=6.7x10⁻¹⁰)
358 (Supplementary Table 2; Supplementary Figure 5a). However, a strongly correlated variant
359 (rs1883711; r²=0.92) lies in a region annotated as a likely enhancer in liver and adipose tissue,
360 the two enriched tissues at this locus (Supplementary Figure 5b). Therefore, rs1883711 was
361 strongly upweighted by FGWAS resulting in a PPA of 0.77 compared to 0.13 for rs2207132. We
362 queried CAD-associated variants for *cis*-eQTLs in CAD-relevant tissues from the STARNET and
363 GTEx studies (Online Methods). [37, 38] The eQTL for *MAFB* observed in liver samples from CAD
364 patients in STARNET suggests that the CAD association is mediated by changes in expression
365 of *MAFB* (encoding MAF bZIP transcription factor B) (Supplementary Table 20). MafB expression
366 in macrophages is upregulated by oxidized LDL stimulation,[39] while MafB deficiency in mice
367 has been shown to increase atherosclerosis by inhibiting foam cell apoptosis.[40]

368

369 Polygenic prioritization of candidate causal genes (PoPS)

370 Combining locus- and similarity-based approaches has been shown to enhance the prioritization
371 of causal genes.[14, 41] However, established similarity-based methods have not leveraged the
372 full polygenic signal to inform gene prioritization. We therefore incorporated a newly developed
373 similarity-based method for gene prioritization, the Polygenic Priority Score (PoPS), which utilizes
374 the full genome-wide association data while excluding a given locus of interest.[15] We applied
375 PoPS to summary-level data from the GWAS meta-analysis using European ancestry individuals

376 from the 1000 Genomes Project as a reference panel.[42] An initial 57,543 features – including
377 data on gene expression, protein-protein interaction networks, and biological pathways – were
378 considered for analysis, of which 21,407 features (37.3%) passed a marginal feature selection
379 step and were input into the final predictive, PoPS model ([Online Methods](#)). We computed a PoPS
380 score for all protein-coding genes within a defined 500kb window around each of the 241 genome-
381 wide associations and prioritized the gene with the highest PoPS score in each locus, resulting in
382 196 prioritized genes. Despite not incorporating locus-specific information, PoPS prioritized many
383 well-established genes implicated in CAD pathogenesis including *LDLR*, *APOB*, *PCSK9*, *SORT1*,
384 *NOS3*, *VEGFA*, and *IL6R* ([Supplementary Tables 21 & 22](#)).

385

386 Next we evaluated groups of features from the final PoPS model to identify those features that
387 were most informative in prioritizing CAD-relevant genes. Hierarchical clustering of the 21,407
388 features yielded 3,149 clusters, which we ranked by their relative contribution to the PoPS scores
389 of prioritized genes (**Figure 4a**). The highest-ranking cluster contained features indicating
390 homeostatic regulation of blood lipids ([Supplementary Table 23](#)). Other top clusters included
391 features related to: function and proliferation of endothelial and smooth muscle cells; the structure
392 and function of the extracellular matrix; and numerous metabolic pathways including those in
393 adipose tissue controlling thermoregulation and turnover of lipids or phospholipids, all well-
394 established pathways and mechanisms in the pathogenesis of CAD[43-45]. In addition, several
395 high-ranking clusters highlighted early developmental processes and signaling pathways
396 involving the cell cycle as less recognized, but important, mediators of CAD risk.

397

398 We then focused on individual loci where the PoPS method informed the prioritization of putative
399 causal genes. For example, rs1807214 was previously reported as genome-wide significant for
400 CAD, but lies in an intergenic region of chromosome 15 at which a causal gene has not been
401 established.[7, 8] Gene expression data from GTEx and STARNET identified *cis*-eQTLs for
402 *ABHD2*, *MFGE8*, and *HAPLN3* ([Supplementary Tables 24 & 25](#)). Prior algorithms combining
403 locus-based approaches have prioritized the nearest gene, *ABHD2*, located 65kb downstream of
404 the sentinel variant.[5, 41] However, PoPS prioritized *MFGE8*, located 108kb upstream of the
405 sentinel, as the most likely causal gene of the ten within 500kb (**Figure 4b**). *MFGE8* encodes
406 lactadherin, an integrin-binding glycoprotein implicated in vascular smooth muscle cell (VSMC)
407 proliferation and invasion, and the secretion of pro-inflammatory molecules.[46, 47] Recently, *in*
408 *vitro* deletion of this intergenic region by CRISPR/Cas9 was found to increase *MFGE8* expression
409 – with no change to *ABHD2* expression – and *MFGE8* knockdown was shown to reduce coronary
410 artery smooth muscle cell and monocyte (THP-1) proliferation, lending functional support to
411 *MFGE8* as a likely causal mediator of the CAD association in this region.[48]

412

413 Systematic prioritization of putative causal genes

414 We applied a consensus-based prioritization framework involving eight similarity-based or locus-
415 based predictors to systematically prioritize likely causal genes for all 241 genome-wide
416 associations (Online Methods; **Figure 5a**). Most likely causal genes were selected for each CAD-
417 associated region based on the highest (unweighted) number of the eight predictors. To test this
418 framework, we generated an *a priori* set of 30 “positive control” genes with established causal
419 roles in CAD and assessed the accuracy of each predictor (Supplementary Table 26). 28 of the
420 30 positive control genes were correctly prioritized as the most likely causal gene based on the
421 highest number of concordant predictors with a median of four concordant predictors per gene
422 (Supplementary Table 27). All predictors demonstrated a high degree of accuracy, including
423 nearest gene (87%), PoPS (80%), eQTL (79%) and mouse knock-outs (95%) (Supplementary
424 Table 27).

425 We were able to prioritize at least one likely causal gene at 206 (85.5%) of the genome-wide
426 associations based on having at least two concordant predictors, and resulting in the prioritization
427 of 185 distinct genes (Supplementary Table 28). We considered 94 of these genes *strongly*
428 prioritized per the presence of three or more concordant predictors (**Figure 5b**). Overall, for 25
429 genes, the prioritized gene was not the nearest gene to the sentinel variant, including *APOC3*,
430 *PLTP* and *LOX*. *Agreement*, defined as the proportion of times that a predictor prioritized the
431 same gene as the most likely causal gene, was high (but imperfect) across predictors, including
432 nearest gene (149 out of 185; 81%), PoPS (142 out of 185; 77%) and eQTLs (75 out of 89; 84%)
433 (**Figure 5a**). *Concordance*, defined as the proportion of times a pair of predictors both provided
434 evidence for the consensus-based causal gene, was variable (Supplementary Figure 6). For
435 example, nearest gene and presence of a missense variant were typically concordant (30/41,
436 73%) whereas monogenic genes and eQTL converged on the consensus-based causal gene
437 much less frequently (5/17, 29%).

438

439 Candidate loci with converging variant- and gene-level evidence

440 Several newly-identified CAD risk loci had strong variant- and gene-level evidence supporting
441 their candidacy for functional interrogation. For example, we identified a CAD-associated region
442 on chromosome 5 that was most strongly enriched in aorta (Supplementary Table 2), and had a
443 95% credible set of just two variants, with an intronic variant (rs4074793) in *ITGA1* having a PPA
444 of 0.95 (**Figure 6a,b**). rs4074793 lies in a region annotated as a likely enhancer in several tissues,
445 and is the lead variant for a strong *cis*-eQTL for *ITGA1* in liver among CAD patients from
446 STARNET (p-value=1.8x10⁻⁷³) (**Figure 6c**). This eQTL was also seen in aorta, subcutaneous fat
447 and mammary artery (**Figure 6d**). No other gene expression signals were seen at this locus, while
448 PoPS also strongly prioritized *ITGA1* as the likely causal gene (Supplementary Table 28). *ITGA1*
449 encodes integrin subunit alpha-1, a widely-expressed protein that forms a heterodimer with
450 integrin beta 1 and acts as a cell surface receptor for extracellular matrix components, such as
451 collagens and laminins. The CAD risk allele (rs4074793-G), or strong proxies, were associated
452 with elevated liver enzymes,[49] C-reactive protein and LDL-cholesterol,[50] highlighting the
453 influence of altered *ITGA1* expression in the liver on lipid pathways as a likely causal pathway to
454 CAD.

455 We identified a novel CAD association near *LIPC* (sentinel variant rs588136, p-value= 7.0×10^{-10} ;
456 Supplementary Table 2) where the risk allele was associated with *higher* levels of HDL-
457 cholesterol, opposite the established observational association. *LIPC* encodes hepatic
458 triacylglycerol lipase, a liver-expressed enzyme that catalyzes the hydrolysis of triglycerides and
459 phospholipids in circulating lipoproteins. The region was most strongly enriched for epigenetic
460 annotation in liver, and FGWAS prioritized a 95% credible set comprising 6 variants with rs588316
461 being the most likely causal variant (PPA=0.50). Variants in the *LIPC* region have been previously
462 associated with circulating HDL-cholesterol levels,[51] but Mendelian randomization studies have
463 reported that HDL-cholesterol is unlikely to play a causal role in CAD risk.[52] Nonetheless, we
464 prioritized *LIPC* as the relevant causal gene per several lines of evidence (Supplementary Table
465 28): (1) PoPS prioritized *LIPC*, and nine of the 10 strongest features related to lipid and lipoprotein
466 metabolism; (2) *LIPC* is the only gene in the region with a *cis*-eQTL – signals in the liver in both
467 STARNET (p-value= 6.0×10^{-27}) and GTEx (p-value= 1.6×10^{-7}); (3) *LIPC* is the only gene in the
468 region with a cardiovascular-relevant phenotype (altered circulating lipid levels) in knock-out mice;
469 (4) the CAD risk allele associated with elevated apolipoprotein-B, LDL-cholesterol and
470 triglycerides in the PheWAS (Supplementary Table 3). The confluence of evidence therefore
471 suggests *LIPC* as the causal gene mediating CAD risk at this region through alterations in liver
472 expression that influence its ability to hydrolyze pro-atherogenic lipids.

473 Finally, we identified a novel association with CAD at a gene-dense region of chromosome 19
474 significantly enriched for epigenetic annotations in adipose, liver, monocytes, and skeletal muscle
475 myoblasts (Supplementary Table 2; Supplementary Table 18). FGWAS identified the CAD
476 sentinel variant (rs7246865) as the most likely causal variant (PPA=0.71). PoPS prioritized
477 *MYO9B* as the likely causal gene over 30 other genes within 500kb (Supplementary Table 21).
478 Support was provided by data from GTEx, where the CAD sentinel variant was a *cis*-eQTL (p-
479 value= 5.3×10^{-8}) for *MYO9B* in tibial artery (Supplementary Table 28). *MYO9B* encodes
480 unconventional myosin-IXb, a myosin protein with Rho-GTPase signaling activity involved in cell
481 migration. Mechanistic *in vitro* and *in vivo* studies have implicated *MYO9B*/RhoA-dependent
482 migration of macrophages in the pathogenesis of abdominal aortic aneurysm, a disease that
483 shares common mechanistic features with CAD.[53] The prioritization of *MYO9B* by PoPS was
484 strongly driven by pathway and PPI-network features pertaining to Rho signaling, proliferation,
485 and chemotaxis (Supplementary Table 21, suggesting a putative causal role for *MYO9B* in CAD
486 pathogenesis, mediated by the proliferation and migration of vascular cell types.

487

488

489 DISCUSSION

490

491 In a genetic discovery analysis involving more than 180,000 cases of CAD and nearly 1 million
492 controls, we identified 241 genome-wide significant associations, including 54 reported here for
493 the first time. We objectively prioritized likely causal variants and effector genes across the 241

494 associations using functionally-informed fine-mapping, a recently-developed genome-wide gene
495 prioritization method (PoPS), and systematic integration of locus-based and similarity-based
496 predictors, with several tailored specifically to cardiovascular disease.

497

498 The large sample size of this study enabled detection of many novel genetic associations with
499 CAD, predominantly weak-effect variants that are common in the population. Our findings suggest
500 that future, larger GWAS - at least those in European ancestry populations - are unlikely to
501 discover many more large-effect common variants (i.e. those with odds ratios greater than 1.05)
502 associated with CAD. In fact, additional associations contributing to the long polygenic tail of CAD
503 risk are likely to arise from the ~650 predominantly weak effect signals among associations that
504 reached the 1% FDR threshold, which in aggregate explained ~36% of the heritability of CAD.
505 Notably, we identified 38 additional novel loci - bringing the total number of novel CAD loci
506 reported here to 68 - when we incorporated recently published GWAS results based on only
507 29,000 CAD cases of East Asian ancestry from Biobank Japan. This observation demonstrates
508 that (future) trans-ethnic genetic analyses should not only identify CAD association signals that
509 differ across ethnicities, but also enhance the yield of overall genetic discovery for CAD.

510

511 Consistent with previous studies, we demonstrated that a genome-wide PRS derived from this
512 GWAS strongly predicts both incident and recurrent CAD.[54-57] Notably, the current PRS
513 demonstrated improved ability to discern those at higher and lower risk of CAD as compared to a
514 widely used PRS derived from an earlier GWAS of ~61,000 CAD cases.[56] While the current
515 PRS provides an improved and powerful tool for genetic risk prediction of CAD in the setting of
516 primary and secondary prevention, our findings suggest that further increases in European-
517 ancestry GWAS sample size may only modestly improve the predictive ability of the CAD PRS.
518 More substantive improvements in polygenic risk prediction may arise from methodological
519 developments, such as approaches that model interactions between variants or incorporate
520 functional information.[58, 59] Moreover, further investigations are required to understand the
521 extent to which genetic discovery analyses that include more non-European ancestry participants
522 will improve the transethnic portability of PRS (and whether this will result in improved prediction
523 across all ancestry groups).[60]

524

525 The weak effects of most CAD-associated variants do not preclude their contribution to important
526 etiological insights with therapeutic implications, as the effects of pharmacologically perturbing
527 identified targets are typically much stronger than those of naturally-occurring genetic variants
528 that are common in the population. For example, we uncovered common variant associations of
529 weak effect at *HMGCR* and *NPC1L1*, which encode the targets of HMG-CoA reductase inhibitors
530 (statins) and ezetimibe, respectively, two of the most effective and commonly prescribed
531 medications for the prevention and management of CAD through lowering blood lipid levels.
532 However, the translation of statistical associations into actionable biology and potential

533 therapeutic targets requires elucidation of causal variants, genes and intermediate pathways,
534 which has lagged behind the rapid growth in genetic association discoveries.

535 Here, we implemented strategies to enhance the identification of putative causal variants and
536 causal genes. By incorporating epigenomic enrichment in disease-relevant tissues - an approach
537 previously shown to improve fine-mapping over broader, disease-agnostic approaches [32] - we
538 prioritized likely causal variants that were not always those with the strongest statistical
539 associations. Using a recently-developed similarity-based tool (PoPS) that exploits the full
540 genome-wide data to identify disease-enriched features, we prioritized likely causal genes for all
541 241 genome-wide associations. Support for the validity of the genes prioritized by PoPS comes
542 from: the high ranking of features of known relevance to atherosclerosis (e.g. lipid metabolism,
543 extracellular matrix processes) from more than 50,000 tested features; the correct assignment of
544 the most likely causal gene at several well-established lipid and non-lipid CAD loci; selection of
545 the likely-correct causal gene over several other candidates in a region, including those in closer
546 proximity to the sentinel (e.g. *MFGE8*); and corroborating evidence at many loci from orthogonal
547 gene prioritization methods, such as eQTLs in disease-relevant tissues.

548

549 As support from multiple, orthogonal lines of evidence increases the likelihood of prioritizing the
550 correct causal gene, we propose an integrative, consensus-based prioritization framework that
551 incorporates eight complementary predictors. By applying this framework to the genome-wide
552 associations with CAD, we provide systematic evidence for the most likely causal gene at over
553 200 associations. Although distance from the sentinel variant has been shown to be a reasonable
554 predictor of causal genes across many phenotypes,[14, 41] our approach provides added
555 confirmation for many associations. For example, at several newly identified associations, such
556 as those nearest *ITGA1*, *LIPC* and *MYO9B*, we provide strong support that these proximal genes
557 are most likely causal through both locus-based and similarity-based evidence. However, our
558 framework prioritized a gene that was not the nearest gene for 15% of associations. These
559 included well-known genes such as *APOC3* and *PLTP*, as well as several genes with less well-
560 established, but plausible, roles in CAD, including *MFGE8*. While experimental evidence is
561 required to confirm causal mechanisms, we provide a prioritization framework yielding evidence-
562 based candidates that may be amenable to functional follow-up. Future efforts to improve gene
563 prioritization for CAD may include addition of further disease-specific lines of evidence, such as
564 data from a broader range of relevant cell types (e.g. vascular smooth muscle cells) or high-
565 throughput assays (e.g. genome-wide CRISPR screens).

566

567

568

569

570 **METHODS**

571

572 **Genetic discovery meta-analysis**

573 Details of the ten *de novo* studies, including the source of participants, case and control definitions
574 and basic participant characteristics are presented in [Supplementary Table 1](#). Ethical approval
575 and informed consent were obtained for all participating studies. With the exception of UK Biobank
576 (which used the ThermoFisher UK Biobank Axiom array), studies used Illumina genotyping
577 arrays. Most studies used the Haplotype Reference Consortium v1.1 panel for imputation, but
578 several utilized local whole-genome sequence data for improved imputation. Study-specific
579 sample and variant filters were applied before additive logistic (or logistic mixed) models were
580 run, with CAD status as the outcome and study-specific covariates, including accounting for
581 potential ancestry effects.

582

583 We performed an inverse variance weighted meta-analysis on the betas and standard errors
584 using METAL,[61] combining the results from the ten *de novo* studies with previously published
585 summary statistics. To maximize the variant-specific sample size, we used summary statistics
586 from either (a) a previous 1000 Genomes-imputed GWAS meta-analysis of up to 60,801 CAD
587 cases and 123,504 CAD-free controls;[7] (b) a meta-analysis of ~79,000 variants in up to 88,192
588 CAD cases and 162,544 controls, predominantly based on the Illumina CardioMetaboChip
589 array;[2] or (c) a meta-analysis ~184,000 variants in up to 42,335 CAD cases and 78,240 controls
590 based on the Illumina Exome array.[10, 16] From each meta-analysis, we dropped variants which
591 were only present in one study or had fewer than 30,000 cases in total from all contributing
592 studies. Where a variant was found in multiple meta-analyses, we kept the result which had the
593 highest total number of 'effective cases' across studies (approximated within each study as the
594 variant-specific number of CAD cases multiplied by the imputation quality score). Finally, to avoid
595 false positive associations driven by an extreme result in a single study, we filtered variants with
596 a meta-analysis $p\text{-value} \leq 5.0 \times 10^{-6}$ that did not have a $p\text{-value} < 0.2$ in at least two studies for which
597 the direction of effect was consistent with the overall meta-analyses effect estimate. Our final
598 dataset included 20,073,070 variants after filtering.

599

600 **Joint association analysis**

601 We performed joint association analysis using GCTA software.[62] This approach fits an
602 approximate multiple regression model using summary-level meta-analysis statistics and LD
603 corrections estimated from a reference panel (here the UKBB sample using European ancestry
604 participants only). We adopted a chromosome-wide stepwise selection procedure to select
605 variants and estimate their joint effects at i) a genome-wide significance level ($p_{\text{Joint}} \leq 5.0 \times 10^{-8}$) in
606 the meta-analyzed variants that reached genome-wide significance ($n=18,348$), ii) an FDR 1% p -

607 value cut-off ($p_{\text{Joint}} \leq 2.52 \times 10^{-5}$) in the 1% FDR variant list ($n=47,622$). We identified 241
608 independent variants at the genome-wide significance threshold and 897 independent variants
609 within the 1% FDR list.

610

611 **Identifying previously reported regions and associations**

612 To identify regions of the genome previously reported as having associations with CAD, we first
613 collapsed variants reaching genome-wide significance by clumping variants within 500kb of each
614 other into a single locus. We compared these regions with all variants previously found to be
615 associated with CAD at a genome-wide level of significance ($p\text{-value} \leq 5.0 \times 10^{-8}$) from previous
616 large-scale genetic association studies of CAD. Regions were annotated as 'known' if they
617 included a previously reported CAD-associated variant. To assess which of our associations were
618 previously reported or novel, we examined the pairwise correlation between each of our 241
619 genome-wide significant sentinel variants and any nearby previously reported variants, defining
620 'novel' as having $r^2 < 0.2$ in UK Biobank European ancestry participants.

621

622 **Phenome-wide association study (PheWAS) in UK Biobank**

623 To understand the spectrum of phenotypic consequences of our 241 independent associations
624 with CAD, we conducted a phenome-wide association study in the UK Biobank. For analyses, we
625 selected 53 cardiovascular and non-cardiovascular diseases and 33 continuous traits. A complete
626 list of the phenotypes assessed, details on disease definitions, and relevant sample sizes are
627 provided in [Supplementary Tables 29 & 30](#). We limited analyses to UK Biobank participants of
628 European genetic ancestry as defined by principal components analysis, and excluded one
629 individual in each pair with *KING* coefficient > 0.0884 , indicating 2nd degree or closer relatedness
630 ($n=393,461$). In sensitivity analyses, the PheWAS was repeated after excluding cases of CAD
631 (remaining $n=360,255$). For disease phenotypes, we performed logistic regression adjusted for
632 age, sex, genotyping array, and the first five principal components. An association with a disease
633 phenotype was deemed significant at a Bonferroni-corrected threshold of $p\text{-value} < 3.9 \times 10^{-6}$ (53
634 diseases x 241 genetic variants). Continuous phenotypes were residualized after adjusting for
635 age, sex, genotyping array, and the first five principal components; linear regression was
636 performed on residuals following inverse-normal transformation. For analysis of glycaemic traits
637 (hemoglobin A1c and serum glucose), participants with type 1 or type 2 diabetes were excluded.
638 An association with a disease phenotype was deemed significant at a Bonferroni-corrected
639 threshold of $P\text{-value} < 6.3 \times 10^{-6}$ (33 continuous traits x 241 genetic variants).

640

641 **Rare variant analyses**

642 Variant annotation for autosomes was performed using Variant Effect Predictor v96.0 with
643 LOFTEE plugin on version three imputed data and variants with an information score ≥ 0.8 . [63,

644 64] Various gene-based groupings were tested (Supplementary Table 4) and allele frequencies
645 from the entire UK Biobank cohort were used for groupings. Variants (n=64,102) were considered
646 to be in a gene if they fell within the gene coordinates as defined by GENCODE v19. Gene-based
647 association tests were performed in SAIGE-GENE v0.35.8.5 using a white British subset of UK
648 Biobank (28,683 CAD cases and 367,783 controls).[65] Software defaults were used except in
649 step 0 the number of markers for sparse matrix was 2000, and in step 1, the tolerance for
650 preconditioned conjugate gradient to converge was 0.01 and variance ratios were estimated
651 across MAC categories. Two variants were required in each gene for testing. Covariates in the
652 model included the genotyping array, the first five principal components calculated in the white
653 British subset of samples, birth year, and sex. Burden, SKAT, and SKAT-O tests were performed
654 for each gene. As no strong signals were observed except for the *PCSK9* gene, we did not extend
655 our rare variant testing to other studies.

656

657 **Sex-specific analysis**

658 We performed a sex-stratified GWAS analysis in UK Biobank following the same phenotype
659 definition and sample exclusions with the main analysis. We used the SAIGE software and
660 adjusted our single-variant association analysis for the first five genetic principal components and
661 the genotyping array, separately for men and women.[66] Based on promising initial results in UK
662 Biobank, we collated sex-stratified GWAS summary statistics from an additional 16 datasets
663 (Supplementary Table 6). All sex-specific summary statistics were checked for quality control
664 (QC) cohort-wise to exclude poorly imputed variants ($\text{info} < 0.4$), improbable betas ($> |4|$) and
665 significant deviations from Hardy-Weinberg Equilibrium ($p\text{-value} < 1.0 \times 10^{-9}$). Cohort-wise sex-
666 specific q-q plots were generated and inspected and the genomic inflation statistic (λ) was also
667 calculated. Association summary statistics from all 17 studies were combined via inverse-variance
668 weighted meta-analysis in GWAMA.[67, 68] We implemented three different types of meta-
669 analysis: a) a sex-specific meta-analysis, where summary statistics were combined separately for
670 men and women; b) a sex-combined meta-analysis, where effect estimates from men and women
671 were combined assuming no between-sex heterogeneity; and c) a sex-differentiated meta-
672 analysis, where sex-specific estimates were combined while allowing for heterogeneity between
673 men and women. We excluded genetic variants that had a minor allele count < 10 or minor allele
674 frequency < 0.01 , were only present in one study, or had a sample size below the median sample
675 size in the sex-combined meta-analysis. To identify significant sex-differentiated genetic variants,
676 we considered variants that had a $p\text{-value} \leq 5.0 \times 10^{-8}$ from the sex-differentiated meta-analysis and
677 a sex-heterogeneity $p\text{-value} \leq 0.01$. Among the significantly associated genetic variants we then
678 applied a 500kb pruning to identify the sex-differentiated CAD loci.

679

680 **False discovery rate (FDR) estimation**

681 The false discovery rate (FDR) following the meta-analysis was assessed using the 'qvalue' R
682 package. We generated q-values for all 20.1M variants. The p-value cut-off for a q-value of 1%

683 was 2.52×10^{-5} and there were 47,622 variants reaching that threshold. Joint conditional analysis
684 was performed using GCTA (as described earlier) to identify approximately independent
685 association signals.

686

687 **Estimation of heritability explained**

688 Heritability calculations were based on a multifactorial liability-threshold model, implemented in
689 the INDI-V calculator (<http://cnsngenomics.com/shiny/INDI-V/>), under the assumption of a baseline
690 population risk (K) of 0.0719 and a twin heritability (H_L^2) of 0.4.[69, 70] Single-variant regression
691 estimates from the meta-analysis summary statistics were used to estimate heritability for the
692 sentinel variants at the 241 conditionally independent genome-wide significant associations and
693 the 897 conditionally independent associations reaching the 1% FDR threshold. To account for
694 correlation between variants, multiple regression estimates from the GCTA joint association
695 analysis were also used to estimate heritability for both sets of variants.

696

697 **Trans-ethnic comparison**

698 For trans-ethnic comparison we used summary statistics from a recent GWAS of 29,319 CAD
699 cases and 183,134 controls from the Biobank Japan [3]. 199 of the 241 sentinel variants from our
700 primary meta-analysis were also found in the Biobank Japan study; after aligning effect alleles,
701 we compared the beta estimates and minor allele frequencies using Pearson's correlation
702 coefficient. To investigate the effect of outliers on the between-ancestry correlation of beta
703 estimates, we re-estimated the correlation coefficient after excluding three strong outliers (at
704 *ATXN2*, *FER*, and *SLC22A1*). We then performed an inverse variance weighted meta-analysis
705 on the beta estimates and standard errors, incorporating summary results from Biobank Japan
706 and those from all other studies in our primary meta-analysis. After trans-ethnic meta-analysis,
707 we again dropped variants which were only present in one study or had fewer than 30,000 cases
708 in total from all contributing studies, leaving 23,333,163 variants after filtering. We then collapsed
709 variants reaching genome-wide significance ($p\text{-value} \leq 5.0 \times 10^{-8}$) by clumping variants within 500kb
710 into a single locus.

711

712 **Derivation and training of polygenic risk scores**

713 Polygenic risk scores (PRS) were derived using one of two methods – pruning and thresholding
714 or the LDpred computational algorithm (LDpred v.1.0), using 503 European ancestry individuals
715 derived from the 1000 Genomes Project study as the linkage disequilibrium reference panel.[42]
716 To evaluate the added utility of our GWAS for the prognostication of CAD risk, we compared two
717 sets of scores using effect estimates from either the current meta-analysis or from our previous
718 1000 Genomes-imputed GWAS of CAD involving ~60,000 cases.[7] For each derivation method
719 and summary statistic, we constructed a range of scores of varying sizes drawing from common

720 genetic variants that overlapped between the current meta-analysis, the earlier 1000 Genomes-
721 imputed CAD GWAS, and our training/validation datasets from the Malmö Diet and Cancer (MDC)
722 Study.

723
724 Pruning and thresholding-based scores were created using a combination of p-value (1, 0.5,
725 $0.05, 5 \times 10^{-3}, 5 \times 10^{-4}, 5 \times 10^{-5}, 5 \times 10^{-6}, 5 \times 10^{-7}, 5 \times 10^{-8}$) and r^2 (0.2, 0.4, 0.6, 0.8, 0.99) thresholds,
726 yielding 45 distinct PRS for each of the two GWAS summary statistics utilized (90 total pruning
727 and thresholding-based scores). LDpred-based scores were constructed incorporating all
728 available SNPs, HapMap3 SNPs (gs://gnomad-
729 public/resources/grch37/hapmap/hapmap_3.3.b37.vcf.bgz), or a soft LD-clumping approach
730 using combinations of p-value (0.05, 0.5, 1) and r^2 (0.2, 0.4, 0.6, 0.8, 0.99) thresholds (17 total
731 sets of input variants). Additionally, we employed a tuning parameter (ρ) for LDpred, which
732 represents the fraction of causal variants, and tested all LDpred-based scores across a range of
733 ρ parameters (1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 and an infinitesimal model), yielding 136 distinct
734 PRS per summary statistic utilized (272 total LDpred-based PRS).

735
736 PRS were computed using variants with high-quality imputation results available in MDC, defined
737 by information score (INFO) > 0.3. For each participant, the raw PRS was generated by
738 multiplying the genotype dosage for each risk-increasing allele by its respective weight and then
739 summing across all variants in the score using PLINK2 software. To permit adjustment for genetic
740 ancestry, principal components of ancestry were computed using the EIGENSOFT software
741 package. The calculated raw PRS was ancestry-adjusted by taking the residual of a linear
742 regression model that predicted PRS using the first ten principal components.

743 We trained all pruning and thresholding and LDpred PRS (362 total scores) in a subset of the
744 Malmö Diet and Cancer Study ($n=22,872$; $n_{\text{incident_cases}}=3,307$). Cox proportional hazard models
745 were used to assess the time-to-event relationship between each PRS and incident CAD with or
746 without adjustment for age and sex. Bootstrapping analysis was performed (100 iterations) and
747 the mean hazard ratio (HR) and mean area under the receiver operator characteristic curve (AUC;
748 as calculated by Harrell's C-statistic) were reported as performance metrics to rank scores within
749 each of four categories as classified by the PRS derivation method (pruning and thresholding;
750 LDpred) and effect estimates utilized (2015 CAD GWAS; Current meta-analysis). Metrics for the
751 top-performing PRS in each category were compared by Wilcoxon rank-sum test based on results
752 of bootstrapping analyses.

753

754 **Primary event prediction analyses in the Malmö Diet and Cancer study (MDC)**

755 The Malmö Diet and Cancer Study is a prospective, population-based cohort that enrolled 30,447
756 participants between 1991 and 1996 ranging in age from 44 to 73 years. Baseline information on
757 lifestyle and clinical factors was collected using a detailed questionnaire as previously
758 described.[71] From the total study population, 28,556 participants (94%) who had genetic data
759 available and were free of CAD at time of enrollment were analyzed. A subset of 5685 randomly
760 selected participants, that comprised the Malmö Diet and Cancer Cardiovascular Cohort, had

761 blood cholesterol concentrations recorded. Incident cases of CAD had either fatal or nonfatal
762 myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary angioplasty
763 or death due to CAD. Incident event adjudication was available through December 31, 2016.
764 Genotyping was performed using the Illumina GSA v1 genotyping array. Of 29,304 samples which
765 underwent genotyping and were free from CAD at baseline, 28 556 (97%) were retained after
766 quality control procedures that removed low-quality samples (discordance between reported and
767 genetically inferred sex, low call rate (<90%), and sample duplicates). With respect to genetic
768 variants, quality control was performed with removal of those not in Hardy-Weinberg equilibrium
769 ($p\text{-value} < 1 \times 10^{-15}$). Imputation was then performed using the Haplotype Reference Consortium
770 reference panel.

771
772 Cox proportional hazard models were used to assess the time-to-event relationship between each
773 PRS and incident CAD events; baseline models were adjusted for age and sex only, and then
774 subsequently for established risk factors for CAD (total cholesterol, HDL cholesterol, systolic
775 blood pressure, body mass index, type 2 diabetes, current smoking status, and family history of
776 CAD). Harrell C-statistics were estimated using Cox proportional hazard analysis over a 21-year
777 follow-up period to assess the discrimination of the PRS.

778

779 **The FOURIER trial (and genetic subset)**

780 The FOURIER trial was a multinational, randomized, double-blind, placebo-controlled trial of the
781 efficacy of evolocumab in patients with clinically evident atherosclerotic cardiovascular
782 disease.[29] The key inclusion criteria for the trial were age between 40 and 85 years, LDL
783 cholesterol of 70 mg/dl or greater or non-HDL-C of 100 mg/dl or greater, and a history of either
784 myocardial infarction, non-hemorrhagic stroke, or symptomatic peripheral artery disease. The
785 genetic sub-study included all participants in FOURIER who provided consent for genetic
786 analyses at enrollment into the trial and had genotyped data that passed quality control (QC), and
787 were of European ancestry. The final genetic cohort comprised of 14,298 unrelated European-
788 ancestry participants, of whom 7,135 were in the placebo arm of the trial. There were no clinically
789 important differences between the overall trial participants and the participants in the genetic
790 subset.

791

792 **Secondary event prediction analyses in the FOURIER trial**

793 The two optimal PRS (“2021 PRS” and “2015 PRS”) were calculated using the genotype dosage
794 for each allele, multiplied by its weight, and then summed across all variants. Patients received a
795 raw score standardized per 1-SD (continuous), as well as a percentile score relative to the total
796 cohort. All scoring was performed using PLINK v2.0 (www.cog-genomics.org/plink/2.0/).[72]
797 Model goodness-of-fit was evaluated using the concordance statistic and the Akaike’s Information
798 Criterion (AIC). R version 3.6.1 was used for statistical analyses.

799

800 The clinical outcome of interest was recurrent major coronary events, defined as myocardial
801 infarction, coronary revascularization or death from CAD ($n_{\text{incident_cases}}=673$). Participants in the
802 genetic cohort were followed for a median of 2.3 years. All endpoints were formally adjudicated
803 by a blinded clinical events committee during the trial. A Cox model was used to determine the
804 hazard ratio per 1 standard deviation higher level of the polygenic risk score and for the extreme
805 deciles compared to the middle 80%. Analyses were adjusted for age, sex, and ancestry (using
806 principal components 1-5).

807

808 **Identifying protein-altering variants**

809 To identify protein-altering variants among our genome-wide significant associations, we took the
810 241 sentinel variants and their LD proxies at $r^2 \geq 0.8$ as estimated in the European ancestry subset
811 of UK Biobank, and annotated them using the Ensembl Variant Effect Predictor (VEP).[64] We
812 selected for each sentinel variant any proxies identified as having a 'high' (i.e. stop-gain and stop-
813 loss, frameshift indel, donor and acceptor splice-site and initiator codon variants) or 'moderate'
814 (i.e. missense, in-frame indel, splice region) consequence and recorded the gene that the variant
815 disrupts.

816

817 **Functional GWAS analysis**

818 To fine-map loci and identify credible functional variants, we applied the FGWAS software.[32]
819 The software integrates GWAS summary statistics with epigenetic data and we used the
820 ChromHMM-derived states from the NIH Roadmap Epigenomics Consortium on a selection of ten
821 CAD relevant cell/tissue types (adipose nuclei, aorta, human skeletal muscle myoblasts [HSMM],
822 liver, human umbilical vein endothelial cells [HUVEC], kidney, adrenal gland, pancreatic islets,
823 primary monocytes and T-cells from peripheral blood).[73, 74] In order to maximize our search
824 space to find functional elements we prepared a custom state by merging likely functional
825 ChromHMM states (enhancers, transcription start sites [TSS], repressed polycomb, transcription
826 at 5' and 3' of gene) for each genomic position. We reweighted the GWAS by running a null model
827 and then a model containing the custom annotation for each of the ten tissues. The regions of the
828 genome that showed strong enrichment ($>3SD$ increment in Bayes Factor [BF]) and had a
829 genome-wide significant CAD-associated variant ($p\text{-value} < 5.0 \times 10^{-8}$) were selected. For each
830 region, we identified the tissue that showed maximum increment in BF and then constructed a
831 95% credible functional set of variants based on the ranked posterior probability of association
832 (PPA) for each variant within a region.

833

834 **Expression QTL analysis in CAD-relevant tissues**

835 To examine whether the CAD associations were driven by changes in gene expression in CAD-
836 relevant tissues and cell types, we interrogated the Stockholm-Tartu Atherosclerosis Reverse
837 Network Engineering Task (STARNET) eQTL study and the Genotype-Tissue Expression (GTEx)
838 study.[37, 38] For STARNET we used *cis*-eQTL associations from seven tissues (atherosclerotic
839 aortic root [AOR], atherosclerotic-lesion-free internal mammary artery [MAM], blood [BLD], liver
840 [LIV], subcutaneous fat [SF], skeletal muscle [SKLM], and visceral abdominal fat [VAF]) taken
841 from 600 CAD patients as previously described. We cross-referenced the sentinel CAD variants
842 and their proxies ($r^2 \geq 0.8$) with STARNET eQTLs reaching a 5% FDR for all tissues. To ensure the
843 CAD association and eQTL are likely to be driven by the same causal variant, we retained only
844 those eQTLs where the CAD-associated variant and the lead eQTL variant had $r^2 \geq 0.8$ among
845 European ancestry participants from UK Biobank. For GTEx we followed the same procedure
846 using the v7 data release (<https://www.gtexportal.org/home/datasets>) and restricted to *cis*-eQTLs
847 reaching a 5% FDR from eight tissues (adipose [subcutaneous, visceral omentum], adrenal gland,
848 artery [aorta, coronary, tibial], liver and whole blood).

849

850 **Polygenic prioritization of candidate causal genes (PoPS)**

851 We implemented PoPS, a gene prioritization method designed to leverage the full genome-wide
852 signal to nominate causal genes independent of methods utilizing GWAS data proximal to the
853 gene.[15] PoPS leverages polygenic enrichments of gene features including cell-type specific
854 gene expression, curated biological pathways, and protein-protein interaction networks to
855 compute a polygenic priority score (POPS) and a p-value for each gene without using any genetic
856 association data on the chromosome containing the gene. Specifically, PoPS was used to train a
857 linear model to predict gene-level association scores from gene features. First, PoPS applied
858 MAGMA to GWAS summary statistics using the 1000 Genomes Project reference panel,[42] and
859 computed gene p-values that are derived from the mean chi-square statistic of SNPs within the
860 gene body. The gene p-values were converted to z-scores $z_g = F^{-1}(1 - p_g)$, where F^{-1} was the probit
861 function. This yielded a roughly normally distributed variable that reflects the strength of the
862 association each gene has to the phenotype, which PoPS used as the model target. In total,
863 57,543 features were considered for analysis, including data on gene expression, protein-protein
864 interaction networks, and biological pathways. After marginal feature selection, PoPS used leave
865 one chromosome out (LOCO), generalized least squares, with I2 regularization to learn linear
866 coefficients for the gene features. Finally, using LOCO prediction, PoPS computed a polygenic
867 priority score for each gene.

868

869 **Variants responsible for cardiovascular-relevant monogenic disorders**

870 To identify genes harboring pathogenic variants responsible for cardiovascular-relevant
871 monogenic disorders, we searched the NCBI's ClinVar database
872 (<https://www.ncbi.nlm.nih.gov/clinvar/>) on 26th June 2020. Variants were pruned to those: within
873 ± 500 kb of our CAD sentinel variants; categorized as 'pathogenic' or 'likely pathogenic'; with a

874 listed phenotype; and with either (a) details of the evidence for pathogenicity, (b) expert review of
875 the gene, or (c) a gene that appears in practice guidelines. We then filtered variants that were
876 annotated with a manually curated set of cardiovascular-relevant phenotype terms, including
877 those related to cardiovascular diseases (CAD, cardiovascular disease), CAD risk factors (lipids,
878 metabolism, blood pressure, obesity, platelets), bleeding disorders and relevant cardiac,
879 vasculature or neurological abnormalities ([Supplementary Table 31](#)). Where a variant was
880 annotated with multiple genes, both genes were considered as potentially pathogenic.

881

882 **Phenotyping knock-out mice**

883 Human gene symbols were mapped to gene identifiers (HGNC) and mouse ortholog genes were
884 obtained using Ensembl (www.ensembl.org). Phenotype data for single-gene knock-out models
885 were obtained from the International Mouse Phenotyping Consortium, data release 10.1
886 (www.mousephenotype.org), and from the Mouse Genome Informatics database, data from July
887 2019 (www.informatics.jax.org). For each mouse model, reported phenotypes were grouped
888 using the mammalian phenotype ontology hierarchy into broad categories relevant to CAD:
889 cardiovascular physiology (MP:0001544), cardiovascular morphology (MP:0002127), growth and
890 body weight (MP:0001259), lipid homeostasis (MP:0002118), cholesterol homeostasis
891 (MP:0005278), and lung morphology (MP:0001175). This resulted in mapping from genes to
892 phenotypes in animals ([Supplementary Table 32](#)).

893

894 **Rare variant associations, Mendelian randomization and drug evidence**

895 To inform prioritization of causal genes within 1Mb regions around our genome-wide associations,
896 we reviewed the literature for three sources of evidence: (1) rare coding variants previously
897 associated with CAD, either individually or in aggregate gene-based tests, through whole-exome
898 sequencing or exome array studies; (2) Mendelian randomization studies of gene expression,
899 protein levels or proximal phenotypes that implicate specific genes as causal effector genes for
900 CAD; (3) drugs proven to be effective for cardiovascular-relevant indications and that target
901 specific proteins encoded by genes.

902

903 **Systematic integration of gene prioritization evidence**

904 To systematically prioritize likely causal genes for all 241 genome-wide associations, we
905 integrated eight of the aforementioned similarity-based or locus-based predictors of causal genes:
906 (1) the top two prioritized genes from PoPS; (2) genes with eQTLs in CAD-relevant tissues from
907 STARNET or GTEx; (3) genes containing protein-altering variants that are in strong LD ($r^2 \geq 0.8$)
908 with the CAD sentinel variant; (4) genes harboring variants responsible for monogenic disorders
909 of cardiovascular relevance according to ClinVar; (5) genes containing rare coding variants that
910 have been associated with CAD risk in previous whole-exome sequencing or array-based studies;

911 (6) genes encoding proteins of causal relevance to CAD per Mendelian randomization studies, or
912 that are targets for established cardiovascular drugs; (7) genes that display cardiovascular-
913 relevant phenotypes in knock-out mice from the International Mouse Phenotyping Consortium or
914 Mouse Genome Informatics database; and (8) the nearest gene to the CAD sentinel variant
915 (**Figure 5a**). We prioritized the most likely “causal gene” for each association using a consensus-
916 based approach, selecting the gene with the highest, unweighted sum of evidence across all eight
917 predictors.

918 We tested our approach by evaluating whether 30 (“positive-control”) genes with established
919 relevance to CAD were prioritized as the most likely causal genes within their respective genomic
920 regions. In addition, we defined two measures to summarize the relative contributions of individual
921 predictors and pairs of predictors to the consensus-based approach. Specifically, we defined
922 “*Agreement*” as the proportion of times that an individual predictor prioritized the same gene that
923 was nominated as the most likely causal gene by the consensus-based framework.
924 “*Concordance*” was defined as the proportion of times a pair of predictors both converged on the
925 gene that was nominated as the most likely causal gene by the consensus of the eight predictors.

926

927 **DATA AVAILABILITY**

928 Summary statistics will be made available upon publication through the CARDIoGRAMplusC4D
929 website (<http://www.cardiogramplusc4d.org/>) and the NHGRI-EBI GWAS Catalog
930 (<https://www.ebi.ac.uk/gwas/>) and polygenic risk score weights will be deposited in the Polygenic
931 Score (PGS) Catalog (<https://www.pgscatalog.org/>). Interactive searchable Manhattan plots and
932 a locus-specific epigenome annotation browser for functionally enriched loci are available at:
933 <https://procardis.shinyapps.io/cadgen/>. Regional association plots for all 241 genome-wide
934 significant associations are available for download from
935 <https://drive.google.com/file/d/1AULeR5zAQJldR6uNHidJ6xs5AxOe6i5M/view?usp=sharing>. An
936 interactive searchable browser detailing the locus-specific evidence prioritizing causal variants,
937 genes and pathways is available at the Common Metabolic Disease’s Knowledge Portal (beta
938 version available at: <https://hugeamp.org/method.html?trait=cad&dataset=cardiogram>).

939

940 **CODE AVAILABILITY**

941 Code used in this project is available on reasonable request to the corresponding authors.

942

943

944

945

946 ACKNOWLEDGEMENTS

947 T.K. is supported by the Corona-Foundation (Junior Research Group Translational
948 Cardiovascular Genomics) and the German Research Foundation (DFG) as part of the
949 Sonderforschungsbereich SFB 1123 (B02). J.D. is a British Heart Foundation Professor,
950 European Research Council Senior Investigator, and National Institute for Health Research
951 (NIHR) Senior Investigator. J.C.H. acknowledges personal funding from the British Heart
952 Foundation (FS/14/55/30806) and is a member of the Oxford BHF Centre of Research Excellence
953 (RE/13/1/30181). R.C. has received funding from the British Heart Foundation and British Heart
954 Foundation Centre of Research Excellence. O.G. has received funding from the British Heart
955 Foundation (BHF) (FS/14/66/3129). P.S.dV was supported by American Heart Association grant
956 number 18CDA34110116 and National Heart, Lung, and Blood Institute grant R01HL146860. The
957 Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds
958 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of
959 Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I,
960 HHSN268201700003I, HHSN268201700004I and HHSN268201700005I), R01HL087641,
961 R01HL059367 and R01HL086694; National Human Genome Research Institute contract
962 U01HG004402; and National Institutes of Health contract HHSN268200625226C. The authors
963 thank the staff and participants of the ARIC study for their important contributions. Infrastructure
964 was partly supported by Grant Number UL1RR025005, a component of the National Institutes of
965 Health and NIH Roadmap for Medical Research. The Trøndelag Health Study (The HUNT Study)
966 is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences,
967 NTNU, Norwegian University of Science and Technology), Trøndelag County Council, Central
968 Norway Regional Health Authority, and the Norwegian Institute of Public Health. The K.G. Jebsen
969 Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of
970 Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology; and
971 Central Norway Regional Health Authority. Whole genome sequencing for the HUNT study was
972 funded by HL109946. The GerMIFs gratefully acknowledge the support of the Bavarian State
973 Ministry of Health and Care, furthermore founded this work within its framework of DigiMed Bayern
974 (grant No: DMB-1805-0001), the German Federal Ministry of Education and Research (BMBF)
975 within the framework of ERA-NET on Cardiovascular Disease (Druggable-MI-genes: 01KL1802),
976 within the scheme of target validation (BlockCAD: 16GW0198K), within the framework of the
977 e:Med research and funding concept (AbCD-Net: 01ZX1706C), the British Heart Foundation
978 (BHF)/German Centre of Cardiovascular Research (DZHK)-collaboration (VIAgenomics) and the
979 German Research Foundation (DFG) as part of the Sonderforschungsbereich SFB 1123 (B02)
980 and the Sonderforschungsbereich SFB TRR 267 (B05). This work was supported by the British
981 Heart Foundation (BHF) grant RG/14/5/30893 (P.D.) and forms part of the research themes
982 contributing to the translational research portfolios of the Barts Biomedical Research Centre
983 funded by the UK National Institute for Health Research (NIHR). I.S. is supported by a Precision
984 Health Scholars Award from the University of Michigan Medical School. This work was supported
985 by the European Commission (HEALTH-F2-2013-601456) and the TriPartite Immunometabolism
986 Consortium [TrIC]- NovoNordisk Foundation (NNF15CC0018486), VIAgenomics
987 (SP/19/2/344612), the British Heart Foundation, a Wellcome Trust core award (M.F., H.W.,
988 203141/Z/16/Z) and support from the NIHR Oxford Biomedical Research Centre. M.F. and H.W.

989 are members of the Oxford BHF Centre of Research Excellence (RE/13/1/30181). The views
990 expressed are those of the authors and not necessarily those of the NHS, the NIHR or the
991 Department of Health. C.P.N. and T.R.W. are funded by the British Heart Foundation. C.J.W. is
992 funded by NIH grant R35-HL135824. B.N.W. is supported by the National Science Foundation
993 Graduate Research Program (DGE 1256260). This research was supported by BHF
994 (SP/13/2/30111) and conducted using the UK Biobank Resource (application number 9922). O.M.
995 was funded by the Swedish Heart- and Lung Foundation, the Swedish Research Council, the
996 European Research Council ERC-AdG-2019-885003 and Lund University Infrastructure grant
997 "Malmö population-based cohorts" (STYR 2019/2046). T.R.W. is funded by the British Heart
998 Foundation. I.K., S.Ko., and K.It. are funded by the Japan Agency for Medical Research and
999 Development, AMED, under Grant Numbers JP16ek0109070h0003, JP18kk0205008h0003,
1000 JP18kk0205001s0703, JP20km0405209, and JP20ek0109487. The BioBank Japan is supported
1001 by AMED under Grant Number JP20km0605001. J.L.M.B. acknowledges research support from
1002 NIH R01HL125863, American Heart Association (A14SFRN20840000), the Swedish Research
1003 Council (2018-02529) and Heart Lung Foundation (20170265) and the Foundation Leducq
1004 (PlaqueOmics: Novel Roles of Smooth Muscle and Other Matrix Producing Cells in
1005 Atherosclerotic Plaque Stability and Rupture, 18CVD02. A.V.K. has been funded by
1006 1K08HG010155 from the National Human Genome Research Institute. K.G.A. has received
1007 support from the American Heart Association Institute for Precision Cardiovascular Medicine
1008 (17IFUNP3384001) and a KL2/Catalyst Medical Research Investigator Training (CMeRIT) award
1009 from the Harvard Catalyst (KL2 TR002542). EPIC-CVD was funded by the European Research
1010 Council (268834) and the European Commission Framework Programme 7 (HEALTH-F2-2012-
1011 279233). The coordinating centre was supported by core funding from the: UK Medical Research
1012 Council (G0800270; MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194;
1013 RG/18/13/33946) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The
1014 views expressed are those of the author(s) and not necessarily those of the NIHR or the
1015 Department of Health and Social Care.

1016

1017 **CONFLICTS OF INTEREST**

1018 All deCODE affiliated authors are employees of deCODE/Amgen Inc. The TIMI Study Group has
1019 received institutional research grant support through Brigham and Women's from Abbott, Amgen,
1020 Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi-Sankyo, Eisai,
1021 GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark
1022 Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zora Biosciences. R.C., J.C.H.,
1023 M.I., F.M. work at the Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield
1024 Department of Population Health, which receives research grants from industry that are governed
1025 by University of Oxford contracts that protect its independence, and has a staff policy of not taking
1026 personal payments from industry; further details can be found at
1027 <https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf>. A.S.B
1028 reports grants outside of this work from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Merck,
1029 Novartis and Sanofi. A.B. and L.A.L. are employees of Regeneron Pharmaceuticals and the
1030 spouse of C.J.W. works at Regeneron Pharmaceuticals. J.L.M.B. and A.R. are members of the

1031 board of directors, founders and shareholders of Clinical Gene Networks AB that has an invested
1032 interest in STARNET. J.C.U. has received compensation for consulting from Goldfinch Bio and is
1033 an employee of Patch Biosciences. O.G. became a full-time employee of UCB while this
1034 manuscript was being drafted.

1035 All other co-authors report no conflicts of interest.

1036

1037 **AUTHOR CONTRIBUTIONS**

1038 De novo GWAS: K.G.A., T.J., B.N.W., W.Z., C.R., I.S., L.M.V., B.O.A., D.O.A., A.B., J.D., G.D.,
1039 P.D., P.T.E., J.E., O.G., P.G., D.F.G., U.G., S.M.I.H., A.H., G.H., H.H., K.H., A.K., S.Kat., T.K.,
1040 A.K., L.L., N.A.M., T.M., S.M., L.M.V., M.M., J.B.N., M.M.N., S.P., L.S.R., T.R., C.R., C.T.R.,
1041 M.S.S., H.S., K.S., I.S., G.Thorg., G.Thorl., U.T., M.v.S., and C.J.W.

1042 Discovery meta-analysis: K.G.A., T.J. and A.S.B.

1043 Conditional analysis, FDR analysis, heritability estimation: S.Kan.

1044 Rare variant analysis: B.N.W., W.Z., I.S., and C.J.W.

1045 Sex analysis: S.Kan., P.D., K.G.A., B.O.A., E.B., M.R.B., B.B., A.S.B., R.C., J.D., P.S.deV., J.E.,
1046 M.F., A.G., C.G., U.G., S.M.I.H., G.H., J.C.W., K.H., M.I., T.J., A.K., S.Kat., T.K., A.K., L.L.,
1047 T.M., A.C.M., S.M., L.M.V., M.M., F.M., J.B.N., M.M.N., S.P., T.R., H.S., I.S., M.v.S., H.W.,
1048 C.J.W., B.N.W., P.Z., and W.Z.

1049 PheWAS: K.G.A.

1050 Trans-ethnic analysis: K.G.A., T.J., K.Is., K.It., Y.K., I.K., S.Ko., and A.S.B.

1051 Association of polygenic risk scores: K.G.A., M.W., G.H., C.R., N.A.M., F.K.K., L.A.L., A.B.,
1052 O.M., M.S.S., M.O-M., A.V.K., M.S.S., P.T.E., C.T.R. and S.Kat.

1053 Functionally-informed fine-mapping: A.G., C.G., M.F., J.C.W., R.C., and H.W.

1054 PoPs: E.M.W, H.K.F, K.G.A. and S.Kat.

1055 Mouse knock-outs: P.D.

1056 eQTL data and analysis: A.S.B., T.J., H.S., L.M., J.L.M.B., A.R., and P.D.

1057 Causal gene prioritization: K.G.A., A.S.B., P.S., R.C., A.G., C.G., M.F., J.C.W., and H.W.

1058 Data visualization: C.G., A.G., N.P.B., M.C.C., J.F., D-K.J., A.S.B., and K.G.A.

1059 CARDIoGRAMplusC4D Executive Committee: J.E., N.J.S., H.S., H.W., P.D., R.R., M.F., S.Kat.,
1060 and J.D.

1061 Conceptualization, initiation and oversight: A.S.B., S.Kat, J.D., C.R., N.J.S., H.S., J.E., H.W.,
1062 P.D., C.J.W.

1063 Drafted and edited the manuscript: K.G.A., T.J., A.G., S.Kan., B.N.W., J.D., C.T.R., H.K.F.,
1064 J.C.H., R.C., J.E., N.J.S., H.S., H.W., C.J.W., P.D., S.Kat. and A.S.B.

1065 All authors reviewed the manuscript.

1066

1067 REFERENCES

1068

1069 1. GBD 2019 Diseases and Injuries Collaborators, *Global burden of 369 diseases*
1070 *and injuries in 204 countries and territories, 1990–2019: a systematic analysis for*
1071 *the Global Burden of Disease Study 2019*. Lancet, 2020. **396**(10258): p. 1204-
1072 1222.

1073 2. Howson, J.M., et al., *Fifteen new risk loci for coronary artery disease highlight*
1074 *arterial-wall-specific mechanisms*. Nat Genet, 2017. **49**(7): p. 1113-1119.

1075 3. Ishigaki, K., et al., *Large-scale genome-wide association study in a Japanese*
1076 *population identifies novel susceptibility loci across different diseases*. Nat Genet,
1077 2020. **52**(7): p. 669-679.

1078 4. Klarin, D., et al., *Genetic analysis in UK Biobank links insulin resistance and*
1079 *transendothelial migration pathways to coronary artery disease*. Nat Genet, 2017.
1080 **49**(9): p. 1392-1397.

1081 5. Koyama, S., et al., *Population-specific and trans-ancestry genome-wide analyses*
1082 *identify distinct and shared genetic risk loci for coronary artery disease*. Nat
1083 Genet, 2020. **52**(11): p. 1169-1177.

1084 6. Nelson, C.P., et al., *Association analyses based on false discovery rate implicate*
1085 *new loci for coronary artery disease*. Nat Genet, 2017. **49**(9): p. 1385-1391.

1086 7. Nikpay, M., et al., *A comprehensive 1000 Genomes–based genome-wide*
1087 *association meta-analysis of coronary artery disease*. Nat Genet, 2015. **47**(10):
1088 p. 1121-1130.

- 1089 8. van der Harst, P. and Verweij, N., *Identification of 64 novel genetic loci provides*
1090 *an expanded view on the genetic architecture of coronary artery disease*. *Circ*
1091 *Res*, 2018. **122**(3): p. 433-443.
- 1092 9. Verweij, N., et al., *Identification of 15 novel risk loci for coronary artery disease*
1093 *and genetic risk of recurrent events, atrial fibrillation and heart failure*. *Sci Rep*,
1094 2017. **7**(1): p. 1-9.
- 1095 10. Webb, T.R., et al., *Systematic evaluation of pleiotropy identifies 6 further loci*
1096 *associated with coronary artery disease*. *J Am Coll Card*, 2017. **69**(7): p. 823-
1097 836.
- 1098 11. de Leeuw, C.A., et al., *MAGMA: generalized gene-set analysis of GWAS data*.
1099 *PLoS Comput Biol*, 2015. **11**(4): p. e1004219.
- 1100 12. Pers, T.H., et al., *Biological interpretation of genome-wide association studies*
1101 *using predicted gene functions*. *Nat Commun*, 2015. **6**(1): p. 1-9.
- 1102 13. Barbeira, A.N., et al., *Exploiting the GTEx resources to decipher the mechanisms*
1103 *at GWAS loci*. *bioRxiv*, 2020: p. 814350.
- 1104 14. Stacey, D., et al., *ProGeM: a framework for the prioritization of candidate causal*
1105 *genes at molecular quantitative trait loci*. *Nuc Acid Res*, 2019. **47**(1): p. e3-e3.
- 1106 15. Weeks, E.M., et al., *Leveraging polygenic enrichments of gene features to*
1107 *predict genes underlying complex traits and diseases*. *medRxiv*, 2020: p.
1108 2020.09.08.20190561.
- 1109 16. Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia
1110 Investigators, *Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of*
1111 *coronary disease*. *New Eng J Med*, 2016. **374**(12): p. 1134-1144.
- 1112 17. Engelse, M.A., et al., *Adenoviral activin a expression prevents intimal hyperplasia*
1113 *in human and murine blood vessels by maintaining the contractile smooth muscle*
1114 *cell phenotype*. *Circ Res*, 2002. **90**(10): p. 1128-1134.
- 1115 18. Engelse, M.A., et al., *Human activin-A is expressed in the atherosclerotic lesion*
1116 *and promotes the contractile phenotype of smooth muscle cells*. *Circ Res*, 1999.
1117 **85**(10): p. 931-939.
- 1118 19. Kozaki, K., et al., *Role of activin-A and follistatin in foam cell formation of THP-1*
1119 *macrophages*. *Arterioscler Thromb Vasc Biol*, 1997. **17**(11): p. 2389-2394.
- 1120 20. Zhang, H., Hu, W., and Ramirez, F., *Developmental expression of fibrillin genes*
1121 *suggests heterogeneity of extracellular microfibrils*. *J Cell Biol*, 1995. **129**(4): p.
1122 1165-1176.

- 1123 21. Putnam, E.A., et al., *Fibrillin-2 (FBN2) mutations result in the Marfan-like*
1124 *disorder, congenital contractural arachnodactyly*. Nat Genet, 1995. **11**(4): p. 456-
1125 458.
- 1126 22. Takeda, N., et al., *Congenital contractural arachnodactyly complicated with aortic*
1127 *dilatation and dissection: Case report and review of literature*. Am J Med Genet
1128 A, 2015. **167A**(10): p. 2382-2387.
- 1129 23. Deguchi, J.O., et al., *Matrix metalloproteinase-13/collagenase-3 deletion*
1130 *promotes collagen accumulation and organization in mouse atherosclerotic*
1131 *plaques*. Circulation, 2005. **112**(17): p. 2708-2715.
- 1132 24. Quillard, T., et al., *Selective inhibition of matrix metalloproteinase-13 increases*
1133 *collagen content of established mouse atherosclerosis*. Arterioscler Thromb Vasc
1134 Biol, 2011. **31**(11): p. 2464-2472.
- 1135 25. Romeo, S., et al., *Genetic variation in PNPLA3 confers susceptibility to*
1136 *nonalcoholic fatty liver disease*. Nat Genet, 2008. **40**(12): p. 1461-1465.
- 1137 26. Grant, S.F., et al., *Variant of transcription factor 7-like 2 (TCF7L2) gene confers*
1138 *risk of type 2 diabetes*. Nat Genet, 2006. **38**(3): p. 320–323.
- 1139 27. Purcell, S.M., et al., *Common polygenic variation contributes to risk of*
1140 *schizophrenia and bipolar disorder*. Nature, 2009. **460**(7256): p. 748–752.
- 1141 28. Vilhjálmsson, B.J., et al., *Modeling linkage disequilibrium increases accuracy of*
1142 *polygenic risk scores*. Am J Hum Genet, 2015. **97**(4): p. 576-592.
- 1143 29. Sabatine, M.S., et al., *Rationale and design of the Further cardiovascular*
1144 *OUTcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial*.
1145 Am Heart J, 2016. **173**: p. 94-101.
- 1146 30. Wu, M.-Y., et al., *Inhibition of the plasma SCUBE1, a novel platelet adhesive*
1147 *protein, protects mice against thrombosis*. Arterioscler Thromb Vasc Biol, 2014.
1148 **34**(7): p. 1390-1398.
- 1149 31. Kichaev, G., et al., *Integrating functional data to prioritize causal variants in*
1150 *statistical fine-mapping studies*. PLoS Genet, 2014. **10**(10): p. e1004722.
- 1151 32. Pickrell, J.K., *Joint analysis of functional genomic data and genome-wide*
1152 *association studies of 18 human traits*. Am J Hum Genet, 2014. **94**(4): p. 559-
1153 573.
- 1154 33. Weissbrod, O., et al., *Functionally informed fine-mapping and polygenic*
1155 *localization of complex trait heritability*. Nat Genet, 2020. **52**(12): p. 1355-1363.

- 1156 34. Gupta, R.M., et al., *A genetic variant associated with five vascular diseases is a*
1157 *distal regulator of endothelin-1 gene expression*. *Cell*, 2017. **170**(3): p. 522-533.
1158 e15.
- 1159 35. Prestel, M., et al., *The atherosclerosis risk variant rs2107595 mediates allele-*
1160 *specific transcriptional regulation of HDAC9 via E2F3 and Rb1*. *Stroke*, 2019.
1161 **50**(10): p. 2651-2660.
- 1162 36. Surakka, I., et al., *The impact of low-frequency and rare variants on lipid levels*.
1163 *Nat Genet*, 2015. **47**(6): p. 589-597.
- 1164 37. Franzén, O., et al., *Cardiometabolic risk loci share downstream cis-and trans-*
1165 *gene regulation across tissues and diseases*. *Science*, 2016. **353**(6301): p. 827-
1166 830.
- 1167 38. GTEx Consortium, *Genetic effects on gene expression across human tissues*.
1168 *Nature*, 2017. **550**(7675): p. 204-213.
- 1169 39. Alasoo, K., et al., *Genetic effects on promoter usage are highly context-specific*
1170 *and contribute to complex traits*. *Elife*, 2019. **8**: p. e41673.
- 1171 40. Hamada, M., et al., *MafB promotes atherosclerosis by inhibiting foam-cell*
1172 *apoptosis*. *Nat Commun*, 2014. **5**(1): p. 1-14.
- 1173 41. Mountjoy, E., et al., *Open Targets Genetics: An open approach to systematically*
1174 *prioritize causal variants and genes at all published human GWAS trait-*
1175 *associated loci*. *bioRxiv*, 2020.
- 1176 42. 1000 Genomes Project Consortium, et al., *A global reference for human genetic*
1177 *variation*. *Nature*, 2015. **526**(7571): p. 68-74.
- 1178 43. Wong, D., Turner, A.W., and Miller, C.L., *Genetic insights into smooth muscle*
1179 *cell contributions to coronary artery disease*. *Arterioscler Thromb Vasc Biol*,
1180 2019. **39**(6): p. 1006-1017.
- 1181 44. Bennett, M.R., Sinha, S., and Owens, G.K., *Vascular smooth muscle cells in*
1182 *atherosclerosis*. *Circ Res*. 2016. **118**(4): p. 692-702.
- 1183 45. Fantuzzi, G., and Mazzone, T. *Adipose tissue and atherosclerosis: exploring the*
1184 *connection*. *Arterioscler Thromb Vasc Biol*, 2007. **27**(5): p. 996-1003.
- 1185 46. Chiang, H.-Y., Chu, P.-H., and Lee, T.-H., *MFG-E8 mediates arterial aging by*
1186 *promoting the proinflammatory phenotype of vascular smooth muscle cells*. *J*
1187 *Biomed Sci*, 2019. **26**(1): p. 61.

- 1188 47. Wang, M., Wang, H. H, and Lakatta, E. G., *Milk fat globule epidermal growth*
1189 *factor VIII signaling in arterial wall remodeling*. *Curr Vasc Pharm*, 2013. **11**(5): p.
1190 768-776.
- 1191 48. Soubeyrand, S., et al., *Regulation of MFGE8 by the intergenic coronary artery*
1192 *disease locus on 15q26. 1*. *Atherosclerosis*, 2019. **284**: p. 11-17.
- 1193 49. Chambers, J.C., et al., *Genome-wide association study identifies loci influencing*
1194 *concentrations of liver enzymes in plasma*. *Nat Genet*, 2011. **43**(11): p. 1131-
1195 1138.
- 1196 50. Klarin, D., et al., *Genetics of blood lipids among~ 300,000 multi-ethnic*
1197 *participants of the Million Veteran Program*. *Nat Genet*, 2018. **50**(11): p. 1514-
1198 1523.
- 1199 51. Kathiresan, S., et al., *Six new loci associated with blood low-density lipoprotein*
1200 *cholesterol, high-density lipoprotein cholesterol or triglycerides in humans*. *Nat*
1201 *Genet*, 2008. **40**(2): p. 189-197.
- 1202 52. Voight, B.F., et al., *Plasma HDL cholesterol and risk of myocardial infarction: a*
1203 *mendelian randomisation study*. *Lancet*, 2012. **380**(9841): p. 572-580.
- 1204 53. Ma, D., et al., *Inhibition of KLF5–Myo9b–RhoA pathway–mediated podosome*
1205 *formation in macrophages ameliorates abdominal aortic aneurysm*. *Circ Res*,
1206 2017. **120**(5): p. 799-815.
- 1207 54. Damask, A., et al., *Patients with high genome-wide polygenic risk scores for*
1208 *coronary artery disease may receive greater clinical benefit from alirocumab*
1209 *treatment in the ODYSSEY OUTCOMES trial*. *Circulation*, 2020. **141**(8): p. 624-
1210 636.
- 1211 55. Hindy, G., et al., *Genome-wide polygenic score, clinical risk factors, and long-*
1212 *term trajectories of coronary artery disease*. *Arterioscler Thromb Vasc Biol*, 2020.
1213 **40**(11): p. 2738-2746.
- 1214 56. Khera, A.V., et al., *Genome-wide polygenic scores for common diseases identify*
1215 *individuals with risk equivalent to monogenic mutations*. *Nat Genet*, 2018. **50**(9):
1216 p. 1219-1224.
- 1217 57. Marston, N.A., et al., *Predicting benefit from evolocumab therapy in patients with*
1218 *atherosclerotic disease using a genetic risk score: results from the FOURIER*
1219 *trial*. *Circulation*, 2020. **141**(8): p. 616-623.
- 1220 58. Amariuta, T., et al., *Improving the trans-ancestry portability of polygenic risk*
1221 *scores by prioritizing variants in predicted cell-type-specific regulatory elements*.
1222 *Nat Genet*, 2020. **52**(12): p. 1346-1354.

- 1223 59. Xu, Y., et al., *Learning polygenic scores for human blood cell traits*. bioRxiv,
1224 2020: p. 2020.02.17.952788.
- 1225 60. Duncan, L., et al., *Analysis of polygenic risk score usage and performance in*
1226 *diverse human populations*. Nat Commun, 2019. **10**(1): p. 1-9.
- 1227 61. Willer, C.J., Li, Y., and Abecasis, G.R., *METAL: fast and efficient meta-analysis*
1228 *of genomewide association scans*. Bioinformatics, 2010. **26**(17): p. 2190-2191.
- 1229 62. Yang, J., et al., *Conditional and joint multiple-SNP analysis of GWAS summary*
1230 *statistics identifies additional variants influencing complex traits*. Nat Genet,
1231 2012. **44**(4): p. 369-375.
- 1232 63. Karczewski, K.J., et al., *The mutational constraint spectrum quantified from*
1233 *variation in 141,456 humans*. Nature, 2020. **581**(7809): p. 434-443.
- 1234 64. McLaren, W., et al., *The Ensembl Variant Effect Predictor*. Genome Biol, 2016.
1235 **17**(1): p. 122.
- 1236 65. Zhou, W., et al., *Scalable generalized linear mixed model for region-based*
1237 *association tests in large biobanks and cohorts*. Nat Genet, 2020. **52**(6): p. 634-
1238 639.
- 1239 66. Zhou, W., et al., *Efficiently controlling for case-control imbalance and sample*
1240 *relatedness in large-scale genetic association studies*. Nat Genet, 2018. **50**(9): p.
1241 1335-1341.
- 1242 67. Magi, R., Lindgren, C.M., and Morris, A.P., *Meta-analysis of sex-specific*
1243 *genome-wide association studies*. Genet Epidemiol, 2010. **34**(8): p. 846-853.
- 1244 68. Mägi, R. and Morris, A.P., *GWAMA: software for genome-wide association meta-*
1245 *analysis*. BMC Bioinf, 2010. **11**(1): p. 288.
- 1246 69. Muñoz, M., et al., *Evaluating the contribution of genetics and familial shared*
1247 *environment to common disease using the UK Biobank*. Nat Genet, 2016. **48**(9):
1248 p. 980-983.
- 1249 70. Witte, J.S., Visscher, P.M., and Wray, N.R., *The contribution of genetic variants*
1250 *to disease depends on the ruler*. Nat Rev Genet, 2014. **15**(11): p. 765-776.
- 1251 71. Berglund, G., et al. *The Malmo Diet and Cancer study. Design and feasibility*. J
1252 Intern Med. 1993. **233**(1): p. 45-51.
- 1253 72. Chang, C.C., et al., *Second-generation PLINK: rising to the challenge of larger*
1254 *and richer datasets*. Gigascience, 2015. **4**(1): p. s13742-015-0047-8.

1255 73. Ernst, J. and Kellis, M., *ChromHMM: automating chromatin-state discovery and*
1256 *characterization*. Nat Methods, 2012. **9**(3): p. 215-216.

1257 74. Kundaje, A., et al., *Integrative analysis of 111 reference human epigenomes*.
1258 Nature, 2015. **518**(7539): p. 317-330.

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279


1280 **Table 1. 30 novel loci for CAD.**
1281

Nearest gene	Lead variant rsID	Chr	Position	Effect allele	Non-effect allele	Odds ratio	95% CI	P-value
<i>KDF1</i>	rs79598313	1	27,284,913	T	C	1.10	(1.06-1.14)	3.6x10 ⁻⁸
<i>LOC100131060</i>	rs71646019	1	59,433,354	T	C	1.04	(1.03-1.05)	6.1x10 ⁻¹⁰
<i>OTUD7B</i>	rs67807996	1	149,995,265	A	G	1.04	(1.03-1.05)	1.1x10 ⁻¹²
<i>MIR4432</i>	rs243071	2	60,619,028	A	G	1.03	(1.02-1.04)	2.7x10 ⁻⁸
<i>SAP130</i>	rs114192718	2	128,785,663	T	C	1.06	(1.04-1.08)	2.6x10 ⁻⁸
<i>ACVR2A</i>	rs35611688	2	148,377,860	T	C	0.97	(0.96-0.98)	1.5x10 ⁻⁸
<i>LNX1</i>	rs17083333	4	54,572,066	T	G	0.97	(0.96-0.98)	1.2x10 ⁻⁸
<i>ITGA1</i>	rs4074793	5	52,193,125	A	G	0.95	(0.93-0.97)	1.6x10 ⁻⁸
<i>FER</i>	rs112949822	5	108,085,190	A	G	0.95	(0.93-0.96)	1.1x10 ⁻⁹
<i>DMXL1</i>	rs13169691	5	118,448,279	T	C	1.04	(1.03-1.06)	2.6x10 ⁻⁸
<i>FBN2</i>	rs6883598	5	127,926,190	A	C	0.97	(0.96-0.98)	9.7x10 ⁻¹⁰
<i>PTK7</i>	rs1034246	6	43,068,370	T	G	0.97	(0.96-0.98)	6.4x10 ⁻¹⁰
<i>MACC1</i>	rs10486389	7	20,300,416	A	G	0.97	(0.96-0.98)	6.5x10 ⁻¹⁰
<i>C9orf146</i>	rs10961206	9	13,724,051	A	T	1.05	(1.04-1.07)	8.1x10 ⁻¹⁰
<i>ACER2</i>	rs10811183	9	19,436,055	A	G	1.04	(1.02-1.05)	1.6x10 ⁻⁸
<i>C5</i>	rs41312891	9	123,726,749	G	GCAAA	0.94	(0.92-0.96)	5.9x10 ⁻⁹
<i>PLCE1</i>	rs55753709	10	96,029,170	T	C	0.96	(0.95-0.97)	2.2x10 ⁻¹³
<i>R3HCC1L</i>	rs884811	10	99,923,763	C	G	1.03	(1.02-1.04)	3.1x10 ⁻⁹
<i>MMP13</i>	rs1892971	11	102,795,606	A	G	0.96	(0.95-0.97)	5.1x10 ⁻¹⁰
<i>ST3GAL4</i>	rs10790800	11	126,262,638	A	G	1.03	(1.02-1.04)	9.1x10 ⁻⁹
<i>TBX3</i>	rs34606058	12	115,353,368	T	C	0.97	(0.96-0.98)	7.7x10 ⁻⁹
<i>DOCK9</i>	rs8000794	13	99,434,810	C	G	1.03	(1.02-1.04)	4.3x10 ⁻⁸
<i>LIPC</i>	rs588136	15	58,730,498	T	C	0.96	(0.95-0.98)	7.0x10 ⁻¹⁰
<i>UNC13D</i>	rs2410859	17	73,841,285	T	C	1.03	(1.02-1.04)	4.3x10 ⁻⁹
<i>CPLX4</i>	rs11663411	18	56,960,510	T	C	0.97	(0.96-0.98)	2.6x10 ⁻⁸
<i>MYO9B</i>	rs7246865	19	17,219,105	A	G	1.03	(1.02-1.05)	1.9x10 ⁻⁸
<i>RRBP1</i>	rs1132274	20	17,596,155	A	C	1.04	(1.03-1.05)	1.8x10 ⁻⁸
<i>MAFB</i>	rs2207132	20	39,142,516	A	G	1.10	(1.07-1.13)	6.7x10 ⁻¹⁰
<i>ARVCF</i>	rs71313931	22	19,960,184	C	G	0.97	(0.96-0.98)	2.3x10 ⁻⁹
<i>SCUBE1</i>	rs139012	22	43,623,972	A	G	0.97	(0.96-0.98)	2.1x10 ⁻⁸

1282
1283 Positions are according to GRCh37. Odds ratios (and 95% confidence intervals) are for per-allele effect estimates according to
1284 the effect allele.


1285

Figure 1. Common variant association signals for CAD.




Minor allele frequency versus per-allele odds ratio for CAD for common sentinel variant (MAF>5%) associations reaching genome-wide significance or the 1% FDR threshold in our study. Colored circles indicate genome-wide significant associations ($p\text{-value} < 5.0 \times 10^{-8}$) with sentinel variants that are not correlated ($r^2 < 0.2$) with a previously reported variant ('novel' – red), genome-wide significant sentinel variants correlated with a previously reported variant ('known' - blue), and associations reaching the 1% FDR threshold ($p\text{-value} < 2.52 \times 10^{-5}$) in our meta-analysis (grey).

Figure 2. Polygenic prediction of primary and secondary coronary artery disease.



Prognostication of (a) incident coronary artery disease and (b) recurrent coronary events by optimal polygenic risk scores derived from the current meta-analysis of ~180K CAD cases ("2021 PRS" – includes ~2.3 million variants) or a previously reported GWAS meta-analysis of CAD from 2015 involving ~60K CAD cases ("2015 PRS" – includes ~1.5 million variants). 815 incident events were analyzed in the validation subset of the Malmo Diet and Cancer Study and 1,074 recurrent coronary events were analyzed in the FOURIER trial. Cox proportional hazards models were adjusted for age, sex and genetic principal components. Error bars represent 95% confidence intervals of hazard ratio estimates.

Figure 3. Epigenetic enrichment and functionally-informed fine-mapping of CAD loci.



a) Number of tissues/cell-types the 116 regions were enriched in.


b) Distribution of 95% credible set sizes for the 116 enriched regions.

c) Circos plot of epigenetic enrichment for 49 significantly enriched GWAS regions containing a variant with $PPA \geq 0.5$.

The number of regions each tissue showed enrichment in is displayed in the upper right quadrant. The number of regions that show enrichment with a given tissue/cell-type is displayed in the box next to the tissue/cell-type name. The 49 significantly enriched GWAS regions containing a variant with $PPA \geq 0.5$ are colored according to the tissue with the strongest evidence of enrichment for that region. Region names with an asterisk (*) denote those for which all conditionally independent association signals were annotated as being novel. The histogram shows the total number of tissues with enrichment for each region and the links indicate the tissues/cell-types each region was enriched in. The number of 95% credible variants per region is displayed in the outer ring.

HSMM = human skeletal muscle myoblasts; HUVEC = human umbilical vein endothelial cells.

Figure 4: Polygenic priority score (PoPS) informs the identification of causal genes for coronary artery disease (CAD).




(a) Feature clusters contributing to causal gene prioritization. Rank-order plot of 3,149 feature clusters (arising from 21,407 distinct features) contributing to the prioritization of likely causal genes for CAD by PoPS. Similarity-based cluster labels are provided for several top clusters.


(b) Prioritization of *MFGES* for rs1807214. Regional association plot at chromosome 15 demonstrating the prioritization of *MFGES* as the likely causal gene for rs1807214, which lies in an intergenic region of chromosome 15. Genes in the region are plotted by their chromosomal position (X-axis) and PoPS score (Y-axis).

Figure 6. Prioritizing the likely causal variant, gene and pathway at the *ITGA1* locus.

a)



b)



a) Regional association plot from the primary CAD meta-analysis for the *ITGA1* region.

Colored dots represent the position (X-axis) in GRCh37 coordinates and $-\log_{10}(\text{meta-analysis } p\text{-value})$ (Y axis) of each variant in the region. Dots are shaded to represent the r^2 with the lead CAD variant (rs4074793), estimated using a random sample of 5,000 European ancestry participants from the UK Biobank. Recombination peaks are plotted in blue based on estimates of recombination from 1000 Genomes European ancestry individuals.

b) Tissue-specific imputed chromHMM states at the two credible set variants in the *ITGA1* region.

The top track shows the position on chromosome 5 (GRCh37) with respect to the *ITGA1* gene. The second track shows as a vertical orange line the posterior probability (Y-axis) for each variant in the region from the FGWAS fine-mapping, identifying rs4074793 (PPA=0.95) as the likely causal variant. The third track indicates as a black box the position of an enhancer state in each of the 10 CAD-relevant tissues, using custom imputed chromHMM states based on epigenomic data from the NIH Roadmap Epigenomics Consortium project. The yellow vertical line indicates the position of the likely causal variant (rs4074793) with respect to the chromHMM states. rs4074793 is annotated to a chromHMM state for all five tissues that show enrichment in the region. HSMM = human skeletal muscle cells; HUVEC = human umbilical vein endothelial cells; PPA = posterior probability of being the causal variant

c) Effect of rs4074973 on *ITGA1* expression in liver in the STARNET study.


The plot shows the position (X-axis) in GRCh37 coordinates and $-\log_{10}(p\text{-value})$ (Y axis) of each variant in the region. The likely causal CAD variant rs4074973 is circled in black.

d) Associations of rs4074973 with *ITGA1* expression and phenotypes from a phenome-wide association study.

The per-allele association of rs4074973-G (the CAD risk allele) measured in SD units is plotted for each phenotype. The box indicates the point estimate and the horizontal bars represent the 95% confidence intervals. The top panel shows the association estimates for *ITGA1* expression from the STARNET study. The bottom panel shows associations from UK Biobank (liver enzymes and inflammatory markers) and the literature (lipids: Klarin *et al.*, *Nat Genet*, 2018).

ALP = alkaline phosphatase; ALT = alanine aminotransferase; CRP = C-reactive protein; GGT = gamma glutamyltransferase; LDL-c = low-density lipoprotein cholesterol; Tchol = total cholesterol.

c)



d)

